78 results on '"Radsak MP"'
Search Results
2. Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells.
- Author
-
Kansy AG, Ashry R, Mustafa AM, Alfayomy AM, Radsak MP, Zeyn Y, Bros M, Sippl W, and Krämer OH
- Subjects
- Humans, Cell Line, Tumor, Proteolysis drug effects, Ubiquitin-Protein Ligases metabolism, Ubiquitin-Protein Ligases genetics, Adaptor Proteins, Signal Transducing metabolism, Adaptor Proteins, Signal Transducing genetics, Hydroxyurea pharmacology, Hydroxyurea analogs & derivatives, DNA Damage drug effects, Ataxia Telangiectasia Mutated Proteins metabolism, DNA Replication drug effects, Cell Proliferation drug effects, Leukemia pathology, Leukemia drug therapy, Leukemia metabolism, Leukemia genetics
- Abstract
Mammalian cells replicate ~ 3 × 10
9 base pairs per cell cycle. One of the key molecules that slows down the cell cycle and prevents excessive DNA damage upon DNA replication stress is the checkpoint kinase ataxia-telangiectasia-and-RAD3-related (ATR). Proteolysis-targeting-chimeras (PROTACs) are an innovative pharmacological invention to molecularly dissect, biologically understand, and therapeutically assess catalytic and non-catalytic functions of enzymes. This work defines the first-in-class ATR PROTAC, Abd110/Ramotac-1. It is derived from the ATR inhibitor VE-821 and recruits the E3 ubiquitin-ligase component cereblon to ATR. Abd110 eliminates ATR rapidly in human leukemic cells. This mechanism provokes DNA replication catastrophe and augments anti-leukemic effects of the clinically used ribonucleotide reductase-2 inhibitor hydroxyurea. Moreover, Abd110 is more effective than VE-821 against human primary leukemic cells but spares normal primary immune cells. CRISPR-Cas9 screens show that ATR is a dependency factor in 116 myeloid and lymphoid leukemia cells. Treatment of wild-type but not of cereblon knockout cells with Abd110 stalls their proliferation which verifies that ATR elimination is the primary mechanism of Abd110. Altogether, our findings demonstrate specific anti-leukemic effects of an ATR PROTAC., (© 2024 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)- Published
- 2024
- Full Text
- View/download PDF
3. Externalized histones fuel pulmonary fibrosis via a platelet-macrophage circuit of TGFβ1 and IL-27.
- Author
-
Riehl DR, Sharma A, Roewe J, Murke F, Ruppert C, Eming SA, Bopp T, Kleinert H, Radsak MP, Colucci G, Subramaniam S, Reinhardt C, Giebel B, Prinz I, Guenther A, Strand D, Gunzer M, Waisman A, Ward PA, Ruf W, Schäfer K, and Bosmann M
- Subjects
- Humans, Mice, Animals, Mice, Inbred C57BL, Histones, Blood Platelets, Interleukin-27, Idiopathic Pulmonary Fibrosis chemically induced, Idiopathic Pulmonary Fibrosis genetics
- Abstract
Externalized histones erupt from the nucleus as extracellular traps, are associated with several acute and chronic lung disorders, but their implications in the molecular pathogenesis of interstitial lung disease are incompletely defined. To investigate the role and molecular mechanisms of externalized histones within the immunologic networks of pulmonary fibrosis, we studied externalized histones in human and animal bronchoalveolar lavage (BAL) samples of lung fibrosis. Neutralizing anti-histone antibodies were administered in bleomycin-induced fibrosis of C57BL/6 J mice, and subsequent studies used conditional/constitutive knockout mouse strains for TGFβ and IL-27 signaling along with isolated platelets and cultured macrophages. We found that externalized histones (citH3) were significantly ( P < 0.01) increased in cell-free BAL fluids of patients with idiopathic pulmonary fibrosis (IPF; n = 29) as compared to healthy controls ( n = 10). The pulmonary sources of externalized histones were Ly6G
+ CD11b+ neutrophils and nonhematopoietic cells after bleomycin in mice. Neutralizing monoclonal anti-histone H2A/H4 antibodies reduced the pulmonary collagen accumulation and hydroxyproline concentration. Histones activated platelets to release TGFβ1, which signaled through the TGFbRI/TGFbRII receptor complex on LysM+ cells to antagonize macrophage-derived IL-27 production. TGFβ1 evoked multiple downstream mechanisms in macrophages, including p38 MAPK, tristetraprolin, IL-10, and binding of SMAD3 to the IL-27 promotor regions. IL-27RA-deficient mice displayed more severe collagen depositions suggesting that intact IL-27 signaling limits fibrosis. In conclusion, externalized histones inactivate a safety switch of antifibrotic, macrophage-derived IL-27 by boosting platelet-derived TGFβ1. Externalized histones are accessible to neutralizing antibodies for improving the severity of experimental pulmonary fibrosis.- Published
- 2023
- Full Text
- View/download PDF
4. Tumor-infiltrating CCR2 + inflammatory monocytes counteract specific immunotherapy.
- Author
-
Bartneck J, Hartmann AK, Stein L, Arnold-Schild D, Klein M, Stassen M, Marini F, Pielenhofer J, Meiser SL, Langguth P, Mack M, Muth S, Probst HC, Schild H, and Radsak MP
- Subjects
- Humans, CD8-Positive T-Lymphocytes, T-Lymphocytes, Cytotoxic, Immunotherapy, Tumor Microenvironment, Receptors, CCR2, Monocytes, Neoplasms therapy
- Abstract
Tumor development and progression is shaped by the tumor microenvironment (TME), a heterogeneous assembly of infiltrating and resident host cells, their secreted mediators and intercellular matrix. In this context, tumors are infiltrated by various immune cells with either pro-tumoral or anti-tumoral functions. Recently, we published our non-invasive immunization platform DIVA suitable as a therapeutic vaccination method, further optimized by repeated application (DIVA
2 ). In our present work, we revealed the therapeutic effect of DIVA2 in an MC38 tumor model and specifically focused on the mechanisms induced in the TME after immunization. DIVA2 resulted in transient tumor control followed by an immune evasion phase within three weeks after the initial tumor inoculation. High-dimensional flow cytometry analysis and single-cell mRNA-sequencing of tumor-infiltrating leukocytes revealed cytotoxic CD8+ T cells as key players in the immune control phase. In the immune evasion phase, inflammatory CCR2+ PDL-1+ monocytes with immunosuppressive properties were recruited into the tumor leading to suppression of DIVA2 -induced tumor-reactive T cells. Depletion of CCR2+ cells with specific antibodies resulted in prolonged survival revealing CCR2+ monocytes as important for tumor immune escape in the TME. In summary, the present work provides a platform for generating a strong antigen-specific primary and memory T cell immune response using the optimized transcutaneous immunization method DIVA2 . This enables protection against tumors by therapeutic immune control of solid tumors and highlights the immunosuppressive influence of tumor infiltrating CCR2+ monocytes that need to be inactivated in addition for successful cancer immunotherapy., Competing Interests: A-KH, MS, MR are inventors of a patent application submitted by the UMC Mainz EP 18204287.9. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2023 Bartneck, Hartmann, Stein, Arnold-Schild, Klein, Stassen, Marini, Pielenhofer, Meiser, Langguth, Mack, Muth, Probst, Schild and Radsak.)- Published
- 2023
- Full Text
- View/download PDF
5. Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection.
- Author
-
Hartmann AK, Bartneck J, Pielenhofer J, Meiser SL, Arnold-Schild D, Klein M, Stassen M, Schild H, Muth S, Probst HC, Langguth P, Grabbe S, and Radsak MP
- Subjects
- Mice, Humans, Animals, Mice, Inbred C57BL, Imiquimod, Anthralin, CD8-Positive T-Lymphocytes, Immunization, Vaccination, Adjuvants, Immunologic, Neoplasms, Dermatitis
- Abstract
Introduction: Transcutaneous immunization (TCI) is a non-invasive vaccination method promoting strong cellular immune responses, crucial for the immunological rejection of cancer. Previously, we reported on the combined application of the TLR7 agonist imiquimod (IMQ) together with the anti-psoriatic drug dithranol as novel TCI platform DIVA (dithranol/IMQ based vaccination). In extension of this work, we further optimized DIVA in terms of drug dose, application pattern and established a new IMQ formulation., Methods: C57BL/6 mice were treated on the ear skin with dithranol and IMQ-containing ointments together with ovalbumin-derived peptides. T cell responses were determined by flow cytometry and IFN-ɤ ELISpot assay, local skin inflammation was characterized by ear swelling., Results: Applying the adjuvants on separate skin sites, a reduced number of specific CD8
+ T cells with effector function was detectable, indicating that the local concurrence of adjuvants and peptide antigens is required for optimal vaccination. Likewise, changing the order of dithranol and IMQ resulted in an increased skin inflammatory reaction, but lower frequencies of antigen-specific CD8+ T cells indicating that dithranol is essential for superior T cell priming upon DIVA. Dispersing nanocrystalline IMQ in a spreadable formulation (IMI-Sol+) facilitated storage and application rendering comparable immune responses. DIVA applied one or two weeks after the first immunization resulted in a massive increase in antigen-specific T cells and up to a ten-fold increased memory response. Finally, in a prophylactic tumor setting, double but no single DIVA treatment enabled complete control of tumor growth, resulting in full tumor protection., Discussion: Taken together, the described optimized transcutaneous vaccination method leads to the generation of a strong cellular immune response enabling the effective control of tumor growth and has the potential for clinical development as a novel non-invasive vaccination method for peptide-based cancer vaccines in humans., Competing Interests: A-KH and MR are inventors of a patent application submitted by the UMC Mainz EP 18204287.9. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Hartmann, Bartneck, Pielenhofer, Meiser, Arnold-Schild, Klein, Stassen, Schild, Muth, Probst, Langguth, Grabbe and Radsak.)- Published
- 2023
- Full Text
- View/download PDF
6. Cross-presenting Langerhans cells are required for the early reactivation of resident CD8 + memory T cells in the epidermis.
- Author
-
Kamenjarin N, Hodapp K, Melchior F, Harms G, Hartmann AK, Bartneck J, Muth S, Raker VK, Becker C, Brand A, Clausen BE, Radsak MP, Schild H, and Probst HC
- Subjects
- Humans, Memory T Cells, Reinfection metabolism, Epidermis, Antigens, Immunologic Memory, Langerhans Cells, CD8-Positive T-Lymphocytes
- Abstract
Tissue-resident memory CD8
+ T cells (TRM ) reside at sites of previous infection, providing protection against reinfection with the same pathogen. In the skin, TRM patrol the epidermis, where keratinocytes are the entry site for many viral infections. Epidermal TRM react rapidly to cognate antigen encounter with the secretion of cytokines and differentiation into cytotoxic effector cells, constituting a first line of defense against skin reinfection. Despite the important protective role of skin TRM , it has remained unclear, whether their reactivation requires a professional antigen-presenting cell (APC). We show here, using a model system that allows antigen targeting selectively to keratinocytes in a defined area of the skin, that limited antigen expression by keratinocytes results in rapid, antigen-specific reactivation of skin TRM . Our data identify epidermal Langerhans cells that cross-present keratinocyte-derived antigens, as the professional APC indispensable for the early reactivation of TRM in the epidermal layer of the skin.- Published
- 2023
- Full Text
- View/download PDF
7. Effects of intermittent fasting on quality of life tolerance of chemotherapy in patients with gynecological cancers: study protocol of a randomized-controlled multi-center trial.
- Author
-
Schmidt MW, Brenner W, Gebhard S, Schmidt M, Singer S, Weidenbach L, Hahn H, Puzankova D, Blau-Schneider B, Lehnert A, Battista MJ, Almstedt K, Lütkemeyer A, Radsak MP, Mähringer-Kunz A, Krajnak S, Linz VC, Schwab R, Gabriel B, Hasenburg A, and Anic K
- Abstract
Fatigue is a very common side effect during intravenous chemotherapy. Unfortunately, only few effective therapeutic options are available, mostly based on daily activity. In our pilot trial we were able to demonstrate that intermittent fasting can reduce fatigue in healthy people, thus we aimed to assess the effects of the fasting dietary on quality of life during chemotherapy in patients with gynecological cancer, especially on the domain of fatigue. The IFAST trial is designed as a prospective, randomized-controlled, multi-center trial. Participation will be offered to women with gynecological cancers (breast cancer, ovarian cancer including peritoneal and fallopian tube cancers, endometrial cancer and cervical cancer) who are planned to receive intravenous chemotherapy for at least three months. Eligible patients will be randomized 1:1, stratified by tumor type and study center. Primary endpoint is the difference in mean change in fatigue, assessed with the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT- FS
© ). Exploratory secondary endpoints will include general Quality of Life impairment, tolerance of chemotherapy, immunological changes, peripheral cell damage in blood cells, as well as tumor response to chemotherapy. There is new evidence that prolonged fasting periods of 46-96 hours during chemotherapy can positively influence the quality of life during chemotherapy. However, these fasting regiments are not feasible for many patients. Intermittent fasting could be a feasible (manageable) option for many patients to actively improve their quality of life and tolerance to chemotherapy and possibly even enhance the effectiveness of chemotherapy., Trial Registration: https://drks.de, identifier DRKS00031429., Competing Interests: MB reports honoraria and expenses from Pharma Mar AG, Astra Zeneca, TesaroBio GmbH, GSK, Roche, Clovis Oncology and consultant activity to AstraZeneca, Clovis Oncology, Eisai, GSK, MSD, PharmaMar, Roche and Tesaro Bio GmbH. Furthermore, he has received research funding by AstraZeneca, Clovis Oncology, MSD, Eisai and Novartis. None were related to this study. MS reports personal fees from AstraZeneca, BioNTech, Eisai, Lilly, MSD, Novartis, Pantarhei Bioscience, Pfizer, Roche, and SeaGen outside the submitted work. Institutional research funding from AstraZeneca, BioNTech, Eisai, Genentech, German Breast Group, Novartis, Palleos, Pantarhei Bioscience, Pierre-Fabre, and Roche. Travel reimbursement from Pfizer and Roche. In addition, M.S. has a patent for EP 2390370 B1 issued and a patent for EP 2951317 B1 issued. AH reports honoraria and expenses from AstraZeneca, Celgen, Leo Pharma, MedConcept GmbH, Med update GmbH, Medpublico GmbH, Pfizer, PharmaMar GmbH, Pierre Fabre Pharma GmbH, Roche Pharma AG, Tesaro Bio Germany GmbH as well as work as a consultant to MSD SHARP & DOHME GmbH, PharmaMar, Medpublico GmbH, Pierre Fabre Pharma GmbH, Roche Pharma AG and Tesaro Bio Germany GmbH. None were related to this study. RS reports honoraria and expenses from Roche Pharma AG and AstraZeneca GmbH. SS reports honoraria from Lilly, Eisai, and Pfizer as well as expenses from Kite Gilead, all outside of this trial. KAn reports paid lectures by Clovis Oncology, AstraZeneca, Pharma Mar, MSD and Eisai not related to this trial. KAl received speaker honoraria from Roche Pharma AG, Pfizer Pharma GmbH, Seagen, Med publico GmbH and AstraZeneca not related to the current work. All author authors report no conflict of interest. BB-S reports honoraria from Seagen and MSD not related to this trial. ALe reports honoraria from Astra Zeneca and Roche not related to this trial. SK received speaker honoraria from Roche Pharma AG and Novartis Pharma GmbH Germany, research funding from Novartis Pharma GmbH Germany and travel reimbursement from PharmaMar and Novartis Pharma GmbH Germany, non-related to this trial. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Schmidt, Brenner, Gebhard, Schmidt, Singer, Weidenbach, Hahn, Puzankova, Blau-Schneider, Lehnert, Battista, Almstedt, Lütkemeyer, Radsak, Mähringer-Kunz, Krajnak, Linz, Schwab, Gabriel, Hasenburg and Anic.)- Published
- 2023
- Full Text
- View/download PDF
8. Author Correction: Dithranol as novel co-adjuvant for non-invasive dermal vaccination.
- Author
-
Sohl J, Hartmann AK, Hahlbrock J, Bartneck J, Stassen M, Klein M, Bros M, Grabbe S, Marini F, Woods K, Guezguez B, Mack M, Schild H, Muth S, Melchior F, Probst HC, Langguth P, and Radsak MP
- Published
- 2023
- Full Text
- View/download PDF
9. Immunomodulation of neutrophil granulocyte functions by bacterial polyphosphates.
- Author
-
Krenzlin V, Schöche J, Walachowski S, Reinhardt C, Radsak MP, and Bosmann M
- Subjects
- Humans, Mice, Animals, Polyphosphates pharmacology, Interleukin-8, Mice, Inbred C57BL, Cytokines, Bronchoalveolar Lavage Fluid, Escherichia coli, Immunomodulation, Lung, Neutrophils, Lipopolysaccharides pharmacology
- Abstract
Polyphosphates are highly conserved, linear polymers of monophosphates that reside in all living cells. Bacteria produce long chains containing hundreds to thousands of phosphate units, which can interfere with host defense to infection. Here, we report that intratracheal long-chain polyphosphate administration to C57BL/6J mice resulted in the release of proinflammatory cytokines and influx of Ly6G
+ polymorphonuclear neutrophils in the bronchoalveolar lavage fluid causing a disruption of the physiologic endothelial-epithelial small airway barrier and histologic signs of lung injury. Polyphosphate-induced effects were attenuated after neutrophil depletion in mice. In isolated murine neutrophils, long-chain polyphosphates modulated cytokine release induced by lipopolysaccharides (LPS) from Gram-negative bacteria or lipoteichoic acid from Gram-positive bacteria. In addition, long-chain polyphosphates induced immune evasive effects in human neutrophils. In detail, long-chain polyphosphates downregulated CD11b and curtailed the phagocytosis of Escherichia coli particles by neutrophils. Polyphosphates modulated the migration capacity by inducing CD62L shedding resulting in CD62Llow and CD11blow neutrophils. The release of IL-8 induced by LPS was also significantly reduced. Pharmacologic blockade of PI3K with wortmannin antagonized long-chain polyphosphate-induced effects on LPS-induced IL-8 release. In conclusion, polyphosphates govern immunomodulation in murine and human neutrophils, suggesting polyphosphates as a therapeutic target for bacterial infections to restore innate immune defense., (© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.)- Published
- 2023
- Full Text
- View/download PDF
10. Deletion of Cd44 Inhibits Metastasis Formation of Liver Cancer in Nf2 -Mutant Mice.
- Author
-
Gerardo-Ramírez M, Giam V, Becker D, Groth M, Hartmann N, Morrison H, May-Simera HL, Radsak MP, Marquardt JU, Galle PR, Herrlich P, Straub BK, and Hartmann M
- Subjects
- Animals, Humans, Mice, Bile Ducts, Intrahepatic, Genes, Neurofibromatosis 2, Neurofibromin 2 genetics, Neurofibromin 2 metabolism, Bile Duct Neoplasms genetics, Carcinoma, Hepatocellular genetics, Cholangiocarcinoma genetics, Hyaluronan Receptors genetics, Liver Neoplasms genetics, Neurofibromatosis 2 genetics
- Abstract
Primary liver cancer is the third leading cause of cancer-related death worldwide. An increasing body of evidence suggests that the Hippo tumor suppressor pathway plays a critical role in restricting cell proliferation and determining cell fate during physiological and pathological processes in the liver. Merlin (Moesin-Ezrin-Radixin-like protein) encoded by the NF2 (neurofibromatosis type 2) gene is an upstream regulator of the Hippo signaling pathway. Targeting of Merlin to the plasma membrane seems to be crucial for its major tumor-suppressive functions; this is facilitated by interactions with membrane-associated proteins, including CD44 (cluster of differentiation 44). Mutations within the CD44-binding domain of Merlin have been reported in many human cancers. This study evaluated the relative contribution of CD44- and Merlin-dependent processes to the development and progression of liver tumors. To this end, mice with a liver-specific deletion of the Nf2 gene were crossed with Cd44 -knockout mice and subjected to extensive histological, biochemical and molecular analyses. In addition, cells were isolated from mutant livers and analyzed by in vitro assays. Deletion of Nf2 in the liver led to substantial liver enlargement and generation of hepatocellular carcinomas (HCCs), intrahepatic cholangiocarcinomas (iCCAs), as well as mixed hepatocellular cholangiocarcinomas. Whilst deletion of Cd44 had no influence on liver size or primary liver tumor development, it significantly inhibited metastasis formation in Nf2 -mutant mice. CD44 upregulates expression of integrin β2 and promotes transendothelial migration of liver cancer cells, which may facilitate metastatic spreading. Overall, our results suggest that CD44 may be a promising target for intervening with metastatic spreading of liver cancer.
- Published
- 2023
- Full Text
- View/download PDF
11. Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product.
- Author
-
Pielenhofer J, Meiser SL, Gogoll K, Ciciliani AM, Denny M, Klak M, Lang BM, Staubach P, Grabbe S, Schild H, Radsak MP, Spahn-Langguth H, and Langguth P
- Abstract
The present article exemplifies the application of the concept of quality by design (QbD) for the systematic development of a nanoparticulate imiquimod (IMQ) emulsion gel formulation as an investigational medicinal product (IMP) for evaluation in an academic phase-I/II clinical trial for the treatment of actinic keratosis (AK) against the comparator Aldara (EudraCT: 2015-002203-28). The design of the QbD elements of a quality target product profile (QTPP) enables the identification of the critical quality attributes (CQAs) of the drug product as the content of IMQ, the particle-size distribution, the pH, the rheological properties, the permeation rate and the chemical, physical and microbiological stability. Critical material attributes (CMAs) and critical process parameters (CPPs) are identified by using a risk-based approach in an Ishikawa diagram and in a risk-estimation matrix. In this study, the identified CPPs of the wet media ball-milling process's milling time and milling speed are evaluated in a central composite design of experiments (DoEs) approach, revealing criticality for both factors for the resulting mean particle size, while only the milling time is significantly affecting the polydispersity. To achieve a mean particle size in the range of 300-400 nm with a minimal PdI, the optimal process conditions are found to be 650 rpm for 135 min. Validating the model reveals a good correlation between the predicted and observed values. Adequate control strategies were implemented for intermediate products as in-process controls (IPCs) and quality control (QC) tests of the identified CQAs. The IPC and QC data from 13 "IMI-Gel" batches manufactured in adherence to good manufacturing practice (GMP) reveal consistent quality with minimal batch-to-batch variability.
- Published
- 2023
- Full Text
- View/download PDF
12. Dithranol as novel co-adjuvant for non-invasive dermal vaccination.
- Author
-
Sohl J, Hartmann AK, Hahlbrock J, Bartneck J, Stassen M, Klein M, Bros M, Grabbe S, Marini F, Woods K, Guezguez B, Mack M, Schild H, Muth S, Melchior F, Probst HC, Langguth P, and Radsak MP
- Abstract
Transcutaneous immunization (TCI) utilizing the TLR7 agonist imiquimod (IMQ-TCI) induces T cell-driven protective immunity upon application onto intact skin. In our present work, we combine the anti-psoriatic agent dithranol with IMQ-TCI to boost vaccination efficacy (Dithranol/IMQ-based transcutaneous vaccination (DIVA)). Using ovalbumin-derived peptides as model antigens in mice, DIVA induced superior cytolytic CD8
+ T cells and CD4+ T cells with a TH1 cytokine profile in the priming as well as in the memory phase. Regarding the underlying mechanisms, dithranol induced an oxidant-dependent, monocyte-attracting inflammatory milieu in the skin boosting TLR7-dependent activation of dendritic cells and macrophages leading to superior T cell priming and protective immunity in vaccinia virus infection. In conclusion, we introduce the non-invasive vaccination method DIVA to induce strong primary and memory T cell responses upon a single local treatment. This work provides relevant insights in cutaneous vaccination approaches, paving the way for clinical development in humans., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
13. Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors.
- Author
-
Stickdorn J, Stein L, Arnold-Schild D, Hahlbrock J, Medina-Montano C, Bartneck J, Ziß T, Montermann E, Kappel C, Hobernik D, Haist M, Yurugi H, Raabe M, Best A, Rajalingam K, Radsak MP, David SA, Koynov K, Bros M, Grabbe S, Schild H, and Nuhn L
- Subjects
- Adjuvants, Immunologic, Animals, Antigens, Immunity, Cellular, Mice, Mice, Inbred C57BL, Nanogels, Ovalbumin, Cancer Vaccines, Neoplasms therapy, Toll-Like Receptor 7 agonists, Toll-Like Receptor 8 agonists
- Abstract
The generation of specific humoral and cellular immune responses plays a pivotal role in the development of effective vaccines against tumors. Especially the presence of antigen-specific, cytotoxic T cells influences the outcome of therapeutic cancer vaccinations. Different strategies, ranging from delivering antigen-encoding mRNAs to peptides or full antigens, are accessible but often suffer from insufficient immunogenicity and require immune-boosting adjuvants as well as carrier platforms to ensure stability and adequate retention. Here, we introduce a pH-responsive nanogel platform as a two-component antitumor vaccine that is safe for intravenous application and elicits robust immune responses in vitro and in vivo . The underlying chemical design allows for straightforward covalent attachment of a model antigen (ovalbumin) and an immune adjuvant (imidazoquinoline-type TLR7/8 agonist) onto the same nanocarrier system. In addition to eliciting antigen-specific T and B cell responses that outperform mixtures of individual components, our two-component nanovaccine leads in prophylactic and therapeutic studies to an antigen-specific growth reduction of different tumors expressing ovalbumin intracellularly or on their surface. Regarding the versatile opportunities for functionalization, our nanogels are promising for the development of highly customized and potent nanovaccines.
- Published
- 2022
- Full Text
- View/download PDF
14. Physical activity specifically evokes release of cell-free DNA from granulocytes thereby affecting liquid biopsy.
- Author
-
Neuberger EWI, Sontag S, Brahmer A, Philippi KFA, Radsak MP, Wagner W, and Simon P
- Subjects
- DNA Methylation, Exercise physiology, Granulocytes, Humans, Liquid Biopsy, Cell-Free Nucleic Acids genetics
- Abstract
Physical activity impacts immune homeostasis and leads to rapid and marked increase in cell-free DNA (cfDNA). However, the origin of cfDNA during exercise remains elusive and it is unknown if physical activity could improve or interfere with methylation based liquid biopsy. We analyzed the methylation levels of four validated CpGs representing cfDNA from granulocytes, lymphocytes, monocytes, and non-hematopoietic cells, in healthy individuals in response to exercise, and in patients with hematological malignancies under resting conditions. The analysis revealed that physical activity almost exclusively triggered DNA release from granulocytes, highlighting the relevance as a pre-analytical variable which could compromise diagnostic accuracy., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
15. Hybrid Biopolymer and Lipid Nanoparticles with Improved Transfection Efficacy for mRNA.
- Author
-
Siewert CD, Haas H, Cornet V, Nogueira SS, Nawroth T, Uebbing L, Ziller A, Al-Gousous J, Radulescu A, Schroer MA, Blanchet CE, Svergun DI, Radsak MP, Sahin U, and Langguth P
- Subjects
- Animals, Cell Line, Fatty Acids, Monounsaturated chemistry, Female, Heparin chemistry, Humans, Mice, Mice, Inbred BALB C, Optical Imaging, Particle Size, Quaternary Ammonium Compounds chemistry, RNA, Messenger chemistry, Biopolymers chemistry, Lipids chemistry, Nanoparticles chemistry, RNA, Messenger metabolism, Transfection methods
- Abstract
Hybrid nanoparticles from lipidic and polymeric components were assembled to serve as vehicles for the transfection of messenger RNA (mRNA) using different portions of the cationic lipid DOTAP (1,2-Dioleoyl-3-trimethylammonium-propane) and the cationic biopolymer protamine as model systems. Two different sequential assembly approaches in comparison with a direct single-step protocol were applied, and molecular organization in correlation with biological activity of the resulting nanoparticle systems was investigated. Differences in the structure of the nanoparticles were revealed by thorough physicochemical characterization including small angle neutron scattering (SANS), small angle X-ray scattering (SAXS), and cryogenic transmission electron microscopy (cryo-TEM). All hybrid systems, combining lipid and polymer, displayed significantly increased transfection in comparison to lipid/mRNA and polymer/mRNA particles alone. For the hybrid nanoparticles, characteristic differences regarding the internal organization, release characteristics, and activity were determined depending on the assembly route. The systems with the highest transfection efficacy were characterized by a heterogenous internal organization, accompanied by facilitated release. Such a system could be best obtained by the single step protocol, starting with a lipid and polymer mixture for nanoparticle formation.
- Published
- 2020
- Full Text
- View/download PDF
16. ERK3/MAPK6 controls IL-8 production and chemotaxis.
- Author
-
Bogucka K, Pompaiah M, Marini F, Binder H, Harms G, Kaulich M, Klein M, Michel C, Radsak MP, Rosigkeit S, Grimminger P, Schild H, and Rajalingam K
- Subjects
- Animals, Cell Line, Gene Expression Regulation physiology, Heterografts, Humans, Mice, Chemotaxis, Leukocyte physiology, Interleukin-8 metabolism, Mitogen-Activated Protein Kinase 6 metabolism
- Abstract
ERK3 is a ubiquitously expressed member of the atypical mitogen activated protein kinases (MAPKs) and the physiological significance of its short half-life remains unclear. By employing gastrointestinal 3D organoids, we detect that ERK3 protein levels steadily decrease during epithelial differentiation. ERK3 is not required for 3D growth of human gastric epithelium. However, ERK3 is stabilized and activated in tumorigenic cells, but deteriorates over time in primary cells in response to lipopolysaccharide (LPS). ERK3 is necessary for production of several cellular factors including interleukin-8 (IL-8), in both, normal and tumorigenic cells. Particularly, ERK3 is critical for AP-1 signaling through its interaction and regulation of c-Jun protein. The secretome of ERK3-deficient cells is defective in chemotaxis of neutrophils and monocytes both in vitro and in vivo. Further, knockdown of ERK3 reduces metastatic potential of invasive breast cancer cells. We unveil an ERK3-mediated regulation of IL-8 and epithelial secretome for chemotaxis., Competing Interests: KB, MP, FM, HB, GH, MK, MK, CM, MR, SR, PG, HS, KR No competing interests declared, (© 2020, Bogucka et al.)
- Published
- 2020
- Full Text
- View/download PDF
17. Current Progress in Particle-Based Systems for Transdermal Vaccine Delivery.
- Author
-
Pielenhofer J, Sohl J, Windbergs M, Langguth P, and Radsak MP
- Subjects
- Adjuvants, Immunologic, Antigen-Presenting Cells immunology, Dermis cytology, Dermis immunology, Drug Delivery Systems, Electroporation, Humans, Injections, Jet, Langerhans Cells immunology, Liposomes administration & dosage, Lymph Nodes immunology, Nanoparticles administration & dosage, Ovalbumin administration & dosage, Particle Size, Peptide Fragments administration & dosage, Pharmaceutical Vehicles administration & dosage, Sonication, T-Lymphocytes immunology, Administration, Cutaneous, Vaccination methods, Vaccines, Virus-Like Particle administration & dosage
- Abstract
Transcutaneous immunization (TCI) via needle-free and non-invasive drug delivery systems is a promising approach for overcoming the current limitations of conventional parenteral vaccination methods. The targeted access to professional antigen-presenting cell (APC) populations within the skin, such as Langerhans cells (LCs), various dermal dendritic cells (dDCs), macrophages, and others makes the skin an ideal vaccination site to specifically shape immune responses as required. The stratum corneum (SC) of the skin is the main penetration barrier that needs to be overcome by the vaccine components in a coordinated way to achieve optimal access to dermal APC populations that induce priming of T-cell or B-cell responses for protective immunity. While there are numerous approaches to penetrating the SC, such as electroporation, sono- or iontophoresis, barrier and ablative methods, jet and powder injectors, and microneedle-mediated transport, we will focus this review on the recent progress made in particle-based systems for TCI. This particular approach delivers vaccine antigens together with adjuvants to perifollicular APCs by diffusion and deposition in hair follicles. Different delivery systems including nanoparticles and lipid-based systems, for example, solid nano-emulsions, and their impact on immune cells and generation of a memory effect are discussed. Moreover, challenges for TCI are addressed, including timely and targeted delivery of antigens and adjuvants to APCs within the skin as well as a deeper understanding of the ill-defined mechanisms leading to the induction of effective memory responses., (Copyright © 2020 Pielenhofer, Sohl, Windbergs, Langguth and Radsak.)
- Published
- 2020
- Full Text
- View/download PDF
18. Neutrophil extracellular traps impair fungal clearance in a mouse model of invasive pulmonary aspergillosis.
- Author
-
Alflen A, Aranda Lopez P, Hartmann AK, Maxeiner J, Bosmann M, Sharma A, Platten J, Ries F, Beckert H, Ruf W, and Radsak MP
- Subjects
- Animals, Apoptosis, Citrullination genetics, Disease Models, Animal, Humans, Immunity, Innate, Invasive Pulmonary Aspergillosis immunology, Lung pathology, Mice, Mice, Inbred C57BL, Mice, Knockout, Protein-Arginine Deiminase Type 4 genetics, Aspergillus fumigatus physiology, Extracellular Traps metabolism, Invasive Pulmonary Aspergillosis metabolism, Lung metabolism, Neutrophils immunology
- Abstract
Neutrophil extracellular traps (NETs) are formed by polymorphonuclear neutrophils (PMN) and contribute to the innate host defense by binding and killing bacterial and fungal pathogens. Because NET formation depends on histone hypercitrullination by peptidylarginine deiminase 4 (PAD4), we used PAD4 gene deficient (Pad4
-/- ) mice in a mouse model of invasive pulmonary aspergillosis (IPA) to address the contribution of NETs to the innate host defense in vivo. After the induction (24 h) of IPA by i.t. infection with Aspergillus fumigatus conidia, Pad4-/- mice revealed lower fungal burden in the lungs, accompanied by less acute lung injury, TNFα and citH3 compared to wildtype controls. These findings suggest that release of NETs contributes to tissue damage and limits control of fungal outgrowth. Thus inhibition of NETosis might be a useful strategy to maintain neutrophil function and avoid lung damage in patients suffering from IPA, especially in those suffering from preexisting pulmonary disease., Competing Interests: Declaration of Competing Interest The authors have no conflicts of interest to declare., (Copyright © 2019 Elsevier GmbH. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
19. Prognostic factors and outcome of adult allogeneic hematopoietic stem cell transplantation patients admitted to intensive care unit during transplant hospitalization.
- Author
-
Michel CS, Teschner D, Schmidtmann I, Theobald M, Hauptrock B, Wagner-Drouet EM, and Radsak MP
- Subjects
- APACHE, Female, Hospitalization statistics & numerical data, Humans, Intensive Care Units statistics & numerical data, Kidney pathology, Male, Middle Aged, Procalcitonin metabolism, Prognosis, ROC Curve, Retrospective Studies, Hematopoietic Stem Cell Transplantation methods
- Abstract
Patients undergoing allogeneic hematopoietic stem cell transplantation have a high morbidity and mortality, especially after admission to intensive care unit (ICU) during peri-transplant period. The objective of this study was to identify new clinical and biological parameters and validate prognostic scores associated with ICU, short-and long-term survival. Significant differences between ICU survivors and ICU non-survivors for the clinical parameters invasive mechanical ventilation, urine output, heart rate, mean arterial pressure, and amount of vasopressors have been measured. Among prognostic scores (SOFA, SAPSII, PICAT, APACHE II, APACHE IV) assessing severity of disease and predicting outcome of critically ill patients on ICU, the APACHE II score has shown most significant difference (p = 0.002) and the highest discriminative power (area under the ROC curve (AUC) 0.74). An elevated level of lactate at day of admission was associated with poor survival on ICU and the most significant independent parameter (p < 0.001). In our cohort kidney damage with low urine output has a highly relevant impact on ICU, short- and long-term overall survival. The APACHE II score was superior predicting ICU mortality compared to all other tested prognostic scores for patients on ICU during peri-transplant period.
- Published
- 2019
- Full Text
- View/download PDF
20. Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice.
- Author
-
Bialojan A, Sohl J, Rausch J, Aranda Lopez P, Denny M, Langguth P, Hartmann AK, Yagita H, Probst HC, Schild H, and Radsak MP
- Subjects
- Administration, Cutaneous, Allografts, Animals, CD27 Ligand genetics, Cytotoxicity, Immunologic drug effects, Gene Expression, Graft Rejection, Immunization methods, Immunologic Memory drug effects, Immunotherapy methods, Melanoma, Experimental genetics, Melanoma, Experimental immunology, Melanoma, Experimental pathology, Membrane Glycoproteins agonists, Membrane Glycoproteins genetics, Membrane Glycoproteins immunology, Mice, Mice, Inbred C57BL, Ovalbumin administration & dosage, Skin drug effects, Skin immunology, Skin Neoplasms genetics, Skin Neoplasms immunology, Skin Neoplasms pathology, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Cytotoxic pathology, T-Lymphocytes, Helper-Inducer immunology, T-Lymphocytes, Helper-Inducer pathology, Toll-Like Receptor 7 agonists, Toll-Like Receptor 7 genetics, Toll-Like Receptor 7 immunology, CD27 Ligand immunology, CD40 Ligand administration & dosage, Imiquimod administration & dosage, Melanoma, Experimental therapy, Skin Neoplasms therapy, T-Lymphocytes, Cytotoxic drug effects
- Abstract
Transcutaneous immunization (TCI) is a novel vaccination strategy that utilizes skin-associated lymphatic tissue to induce immune responses. Employing T-cell epitopes and the TLR7 agonist imiquimod onto intact skin mounts strong primary, but limited memory CTL responses. To overcome this limitation, we developed a novel imiquimod-containing vaccination platform (IMI-Sol) rendering superior primary CD8
+ and CD4+ T-cell responses. However, it has been unclear whether IMI-Sol per se is restricted in terms of memory formation and tumor protection. In our present work, we demonstrate that the combined administration of IMI-Sol and CD40 ligation unleashes fullblown specific T-cell responses in the priming and memory phase, strongly enhancing antitumor protection in mice. Interestingly, these effects were entirely CD4+ T cell independent, bypassing the necessity of helper T cells. Moreover, blockade of CD70 in vivo abrogated the boosting effect of CD40 ligation, indicating that the adjuvant effect of CD40 in TCI is mediated via CD70 on professional APCs. Furthermore, this work highlights the so far underappreciated importance of the CD70/CD27 interaction as a promising adjuvant target in TCI. Summing up, we demonstrate that the novel formulation IMI-Sol represents a powerful vaccination platform when applied in combination with sufficient adjuvant thereby overcoming current limitations of TCI., (© 2019 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)- Published
- 2019
- Full Text
- View/download PDF
21. Antifungal Drugs Influence Neutrophil Effector Functions.
- Author
-
Ries F, Alflen A, Aranda Lopez P, Beckert H, Theobald M, Schild H, Teschner D, and Radsak MP
- Subjects
- Amphotericin B pharmacology, Interleukin-8 metabolism, Neutrophils drug effects, Nitriles pharmacology, Phagocytosis drug effects, Pyridines pharmacology, Triazoles pharmacology, Voriconazole pharmacology, Antifungal Agents pharmacology, Neutrophils metabolism
- Abstract
There is a growing body of evidence for immunomodulatory side effects of antifungal agents on different immune cells, e.g., T cells. Therefore, the aim of our study was to clarify these interactions with regard to the effector functions of polymorphonuclear neutrophils (PMN). Human PMN were preincubated with fluconazole (FLC), voriconazole (VRC), posaconazole (POS), isavuconazole (ISA), caspofungin (CAS), micafungin (MFG), conventional amphotericin B (AMB), and liposomal amphotericin B (LAMB). PMN then were analyzed by flow cytometry for activation, degranulation, and phagocytosis and by dichlorofluorescein assay to detect reactive oxygen species (ROS). Additionally, interleukin-8 (IL-8) release was measured by enzyme-linked immunosorbent assay. POS led to enhanced activation, degranulation, and generation of ROS, whereas IL-8 release was reduced. In contrast, ISA-pretreated PMN showed decreased activation signaling, impaired degranulation, and lower generation of ROS. MFG caused enhanced expression of activation markers but impaired degranulation, phagocytosis, generation of ROS, and IL-8 release. CAS showed increased phagocytosis, whereas degranulation and generation of ROS were reduced. AMB led to activation of almost all effector functions besides impaired phagocytosis, whereas LAMB did not alter any effector functions. Independent from class, antifungal agents show variable influence on neutrophil effector functions in vitro Whether this is clinically relevant needs to be clarified., (Copyright © 2019 American Society for Microbiology.)
- Published
- 2019
- Full Text
- View/download PDF
22. Dermal CD207-Negative Migratory Dendritic Cells Are Fully Competent to Prime Protective, Skin Homing Cytotoxic T-Lymphocyte Responses.
- Author
-
Hain T, Melchior F, Kamenjarin N, Muth S, Weslati H, Clausen BE, Mahnke K, Silva-Vilches C, Schütze K, Sohl J, Radsak MP, Bündgen G, Bopp T, Danckwardt S, Schild H, and Probst HC
- Subjects
- Animals, Disease Models, Animal, Epitopes, T-Lymphocyte genetics, Epitopes, T-Lymphocyte immunology, Epitopes, T-Lymphocyte metabolism, Histocompatibility Antigens Class I immunology, Histocompatibility Antigens Class I metabolism, Humans, Immunologic Memory, Langerhans Cells metabolism, Mice, Mice, Transgenic, Skin cytology, Skin Diseases, Viral immunology, Skin Diseases, Viral virology, T-Lymphocytes, Cytotoxic metabolism, Vaccinia virus immunology, CD8-Positive T-Lymphocytes immunology, Cross-Priming, Langerhans Cells immunology, Skin immunology, T-Lymphocytes, Cytotoxic immunology
- Abstract
Dendritic cells (DCs) are important inducers and regulators of T-cell responses. They are able to activate and modulate the differentiation of CD4
+ and CD8+ T cells. In the skin, there are at least five phenotypically distinct DC subpopulations that can be distinguished by differential expression of the cell surface markers CD207, CD103, and CD11b. Previous studies have suggested that dermal CD11b- CD207+ conventional type 1 DCs are indispensable for the priming of a skin homing cytotoxic T-lymphocyte response. However, conventional type 1 DCs are also the only skin DC subset capable of cross-presenting exogenous antigens on major histocompatibility complex class I. Thus, it remained unclear whether for antigens that do not require cross-presentation, such as viruses that infect DCs, other DC subtypes in the skin can contribute to cytotoxic T-lymphocyte priming. To address this question, we used a transgenic mouse model that allows inducible expression and presentation of a model antigen on selected subsets of dermal DCs. We show that for antigens presented via the conventional major histocompatibility complex class I presentation pathway, CD207- dermal DCs are fully competent to prime a skin homing cytotoxic T-lymphocyte response that is capable of protection against a local virus challenge and gives rise to skin resident memory CD8+ T cells., (Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
23. Investigation of charge ratio variation in mRNA - DEAE-dextran polyplex delivery systems.
- Author
-
Siewert C, Haas H, Nawroth T, Ziller A, Nogueira SS, Schroer MA, Blanchet CE, Svergun DI, Radulescu A, Bates F, Huesemann Y, Radsak MP, Sahin U, and Langguth P
- Subjects
- Dendritic Cells metabolism, Heparin metabolism, Humans, Particle Size, Scattering, Small Angle, Static Electricity, X-Ray Diffraction, DEAE-Dextran chemistry, Drug Delivery Systems, RNA, Messenger chemistry
- Abstract
mRNA pharmaceuticals represent a new class of therapeutics, with applications, in cancer vaccination, tumour therapy and protein substitution. Formulations are required to deliver messenger RNA (mRNA) to the target sites where induction of genetic transfection following receptor mediated cell uptake & translation is required. In the current study, the cationic polysaccharide diethylaminoethylen (DEAE) - Dextran was selected as a model system carrier for the investigation of polyplex nanoparticle formation together with mRNA as a function of the molar ratio of the components. The structure of the mRNA/Dextran colloids was investigated as a function of the polymer-to-mRNA ratio and correlated with the biological activity determined by cellular transfection with luciferase coding mRNA. Dynamic light scattering (DLS), small angle x-ray scattering (SAXS), and small angle neutron scattering (SANS) with deuterium contrast variation were used to achieve structural insight into the systems. Similarly to previously investigated lipid based systems, colloidally stable particles with confined size were obtained with either excess of positive or negative charge. Highest activity was obtained with positive charge excess. From the scattering experiments information on the internal organization inside the polymer/mRNA systems was derived. Indication for the presence of structural elements in the length scale of ten to 20 nm were found in the excess of dextran, which could be due to either excess or particulate polymer. Information on the molecular organization of the mRNA nanoparticle products may provide a valuable basis for defining critical quality attributes of drug products for pharmaceutical application., (Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
24. Author Correction: ADAMTS-13 regulates neutrophil recruitment in a mouse model of invasive pulmonary aspergillosis.
- Author
-
Alflen A, Prüfer S, Ebner K, Reuter S, Lopez PA, Scharrer I, Banno F, Stassen M, Schild H, Jurk K, Bosmann M, Beckert H, and Radsak MP
- Abstract
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.
- Published
- 2018
- Full Text
- View/download PDF
25. Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita.
- Author
-
Kirschner M, Maurer A, Wlodarski MW, Ventura Ferreira MS, Bouillon AS, Halfmeyer I, Blau W, Kreuter M, Rosewich M, Corbacioglu S, Beck J, Schwarz M, Bittenbring J, Radsak MP, Wilk CM, Koschmieder S, Begemann M, Kurth I, Schemionek M, Brümmendorf TH, and Beier F
- Subjects
- Adult, Dyskeratosis Congenita complications, Female, Follow-Up Studies, Germany epidemiology, Humans, Incidence, Leukemia, Myeloid, Acute epidemiology, Male, Middle Aged, Myelodysplastic Syndromes epidemiology, Prognosis, Young Adult, Biomarkers, Tumor genetics, Dyskeratosis Congenita genetics, Leukemia, Myeloid, Acute genetics, Mutation, Myelodysplastic Syndromes genetics, Telomere Shortening genetics
- Abstract
Dyskeratosis congenita (DKC) is a paradigmatic telomere disorder characterized by substantial and premature telomere shortening, bone marrow failure, and a dramatically increased risk of developing myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). DKC can occur as a late-onset, so-called cryptic form, with first manifestation in adults. Somatic MDS-related mutations are found in up to 35% of patients with acquired aplastic anemia (AA), especially in patients with short telomeres. The aim of our study was to investigate whether cryptic DKC is associated with an increased incidence of MDS-related somatic mutations, thereby linking the accelerated telomere shortening with the increased risk of MDS/AML. Samples from 15 adult patients (median age: 42 years, range: 23-60 years) with molecularly confirmed cryptic DKC were screened using next-generation gene panel sequencing to detect MDS-related somatic variants. Only one of the 15 patients (7%) demonstrated a clinically relevant MDS-related somatic variant. This incidence was dramatically lower than formerly described in acquired AA. Based on our data, we conclude that clonal evolution of subclones carrying MDS-related mutations is not the predominant mechanism for MDS/AML initiation in adult cryptic DKC patients.
- Published
- 2018
- Full Text
- View/download PDF
26. Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses.
- Author
-
Alflen A, Stadler N, Aranda Lopez P, Teschner D, Theobald M, Heß G, and Radsak MP
- Subjects
- Anti-Inflammatory Agents therapeutic use, Cell Count, Humans, Immunity, Innate drug effects, Inflammation drug therapy, Inflammation immunology, Inflammation metabolism, Inflammation pathology, Interleukin-8 metabolism, Neutrophils immunology, Phagocytosis drug effects, Phosphatidylinositol 3-Kinases metabolism, Purines therapeutic use, Quinazolinones therapeutic use, Respiratory Burst drug effects, Signal Transduction drug effects, Anti-Inflammatory Agents pharmacology, Neutrophils drug effects, Purines pharmacology, Quinazolinones pharmacology, Triggering Receptor Expressed on Myeloid Cells-1 metabolism
- Abstract
Triggering receptor expressed on myeloid cells (TREM)-1 on polymorphonuclear neutrophils (PMN) regulates innate immune activation in infectious and non-infectious conditions. TREM-1 ligation activates phosphatidyl-inositol 3 kinase (PI3K) triggering all neutrophil effector functions. As idelalisib is a PI3K inhibitor in clinical use for the treatment of non-Hodgkin lymphomas, we asked whether this inhibitor affects PMN functionalities. We analyzed PMNs from healthy donors or lymphoma patients for oxidative burst, phagocytosis, activation markers and IL-8 release upon TREM-1 or TLR ligation ex vivo. In addition, we performed western blot analyses to characterize the signaling events inhibited by idelalisib and other PI3K inhibitors. Upon TREM-1 ligation, the oxidative burst, degranulation, L-selectin shedding and cytokine release were all strongly reduced in the presence of idelalisib along impaired phosphorylation of P38, AKT and ERK by western blot analyses. In line with this, PMNs from patients receiving idelalisib also displayed an impaired TREM-1 mediated PMN activation ex vivo. In conclusion, PI3K inhibitors might cause a neutropenia-like susceptibility to infections in patients by leading to impaired PMN functionality. This should be considered when evaluating patients for infections treated with such inhibitors in daily clinical routine.
- Published
- 2018
- Full Text
- View/download PDF
27. Diagnostic value of sTREM-1, IL-8, PCT, and CRP in febrile neutropenia after autologous stem cell transplantation.
- Author
-
Michel CS, Teschner D, Wagner EM, Theobald M, and Radsak MP
- Subjects
- Aged, Autografts, Critical Illness, Female, Humans, Male, Middle Aged, C-Reactive Protein metabolism, Calcitonin blood, Febrile Neutropenia blood, Febrile Neutropenia therapy, Interleukin-8 blood, Stem Cell Transplantation, Triggering Receptor Expressed on Myeloid Cells-1 blood
- Abstract
Infections and infectious complications are the major cause of morbidity and mortality in febrile neutropenic patients after autologous stem cell transplantation. Laboratory biomarkers are helpful for early identification of critically ill patients and optimal therapy management. Several studies in adult non-neutropenic patients proposed sTREM-1 as a superior biomarker for identification of septic patients as well as a predictor for survival in these patients compared with procalcitonin (PCT), C-reactive protein (CRP), or interleukin-8 (IL-8). Here, to assess the utility of PCT, CRP, IL-8, and sTREM-1 in febrile neutropenia, 44 patients presenting with febrile neutropenia after autologous stem cell transplantation were recruited in a single-center prospective pilot study. We analyzed PCT and CRP as well as IL-8 and sTREM-1 levels pre- and post-transplantation at defined time points. In 20 of 44 patients, concentration of sTREM-1 was under the detection level at appearance of febrile neutropenia. Mean levels of PCT, IL-8, and CRP were significantly increased in infections of critically ill patients who by dysfunction or failure of one or more organs/system depend on survival from advanced instruments of monitoring and therapy. However, all tested biomarkers could not distinguish between presence and absence of bloodstream infection. The combination of the biomarkers PCT and IL-8 achieved a high sensitivity of 90% and specificity of 74% for the identification of serious complications in febrile neutropenia, whereas the combination of CRP and PCT or IL-8 achieved a high sensitivity of 100%, but with the addition of a low specificity of 47or 41%. In conclusion, we found that the measurement of sTREM-1 concentration at presentation of febrile neutropenia is not useful to identify bacterial bloodstream infections and critically ill patients. PCT and IL-8 are useful biomarkers for the early identification of critically ill patients, compared to CRP and sTREM-1 in febrile neutropenia. PCT or IL-8 in combination with clinical parameters should be considered in routine measurement to identify critically ill patients as early as possible.
- Published
- 2017
- Full Text
- View/download PDF
28. Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity.
- Author
-
Weber ANR, Bittner Z, Liu X, Dang TM, Radsak MP, and Brunner C
- Abstract
Bruton's tyrosine kinase (BTK) was initially discovered as a critical mediator of B cell receptor signaling in the development and functioning of adaptive immunity. Growing evidence also suggests multiple roles for BTK in mononuclear cells of the innate immune system, especially in dendritic cells and macrophages. For example, BTK has been shown to function in Toll-like receptor-mediated recognition of infectious agents, cellular maturation and recruitment processes, and Fc receptor signaling. Most recently, BTK was additionally identified as a direct regulator of a key innate inflammatory machinery, the NLRP3 inflammasome. BTK has thus attracted interest not only for gaining a more thorough basic understanding of the human innate immune system but also as a target to therapeutically modulate innate immunity. We here review the latest developments on the role of BTK in mononuclear innate immune cells in mouse versus man, with specific emphasis on the sensing of infectious agents and the induction of inflammation. Therapeutic implications for modulating innate immunity and critical open questions are also discussed.
- Published
- 2017
- Full Text
- View/download PDF
29. Neuroendocrine Modulation of IL-27 in Macrophages.
- Author
-
Roewe J, Higer M, Riehl DR, Gericke A, Radsak MP, and Bosmann M
- Subjects
- Albuterol pharmacology, Animals, Anthracenes pharmacology, Cells, Cultured, Formoterol Fumarate pharmacology, Inflammation, Interleukin-10 biosynthesis, Interleukin-10 immunology, Interleukins blood, Interleukins genetics, Lipopolysaccharides pharmacology, Macrophage Activation drug effects, Mice, Mice, Inbred C57BL, Poly I-C metabolism, Receptors, Adrenergic drug effects, Shock, Septic, Signal Transduction drug effects, Sulfonamides pharmacology, Sympathetic Nervous System immunology, Sympathetic Nervous System physiology, Thiadiazoles pharmacology, Toll-Like Receptor 3 metabolism, Zymosan pharmacology, Epinephrine pharmacology, Interleukins immunology, Interleukins metabolism, Macrophages drug effects, Macrophages immunology, Norepinephrine pharmacology
- Abstract
Heterodimeric IL-27 (p28/EBV-induced gene 3) is an important member of the IL-6/IL-12 cytokine family. IL-27 is predominantly synthesized by mononuclear phagocytes and exerts immunoregulatory functional activities on lymphocytic and nonlymphocytic cells during infection, autoimmunity or neoplasms. There is a great body of evidence on the bidirectional interplay between the autonomic nervous system and immune responses during inflammatory disorders, but so far IL-27 has not been defined as a part of these multifaceted neuroendocrine networks. In this study, we describe the role of catecholamines (as mediators of the sympathetic nervous system) related to IL-27 production in primary mouse macrophages. Noradrenaline and adrenaline dose-dependently suppressed the release of IL-27p28 in LPS/TLR4-activated macrophages, which was independent of α
1 adrenoceptors. Instead, β2 adrenoceptor activation was responsible for mediating gene silencing of IL-27p28 and EBV-induced gene 3. The β2 adrenoceptor agonists formoterol and salbutamol mediated suppression of IL-27p28 production, when triggered by zymosan/TLR2, LPS/TLR4, or R848/TLR7/8 activation, but selectively spared the polyinosinic-polycytidylic acid/TLR3 pathway. Mechanistically, β2 adrenergic signaling reinforced an autocrine feedback loop of macrophage-derived IL-10 and this synergized with inhibition of the JNK pathway for limiting IL-27p28. The JNK inhibitors SP600125 and AEG3482 strongly decreased intracellular IL-27p28 in F4/80+ CD11b+ macrophages. In endotoxic shock of C57BL/6J mice, pharmacologic activation of β2 adrenoceptors improved the severity of shock, including hypothermia and decreased circulating IL-27p28. Conversely, IL-27p28 was 2.7-fold increased by removal of the catecholamine-producing adrenal glands prior to endotoxic shock. These data suggest a novel role of the sympathetic neuroendocrine system for the modulation of IL-27-dependent acute inflammation., (Copyright © 2017 by The American Association of Immunologists, Inc.)- Published
- 2017
- Full Text
- View/download PDF
30. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
- Author
-
Rausch J, Lopez PA, Bialojan A, Denny M, Langguth P, Probst HC, Schild H, and Radsak MP
- Subjects
- Adjuvants, Immunologic therapeutic use, Aminoquinolines pharmacology, Aminoquinolines therapeutic use, Animals, Antineoplastic Agents, Immunological therapeutic use, CTLA-4 Antigen immunology, Drug Synergism, Flow Cytometry, Humans, Imiquimod, Immunologic Memory drug effects, Immunotherapy methods, Melanoma, Experimental immunology, Melanoma, Experimental mortality, Membrane Glycoproteins antagonists & inhibitors, Mice, Mice, Inbred C57BL, Ovalbumin pharmacology, Ovalbumin therapeutic use, Peptide Fragments pharmacology, Peptide Fragments therapeutic use, Skin Neoplasms immunology, Skin Neoplasms mortality, T-Lymphocytes, Cytotoxic metabolism, T-Lymphocytes, Regulatory metabolism, Toll-Like Receptor 7 antagonists & inhibitors, Xenograft Model Antitumor Assays, Adjuvants, Immunologic pharmacology, Antineoplastic Agents, Immunological pharmacology, CTLA-4 Antigen antagonists & inhibitors, Melanoma, Experimental therapy, Skin Neoplasms therapy, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Regulatory immunology
- Abstract
Background: The epidermal application of the Toll Like Receptor 7 agonist imiquimod and a T-cell peptide epitope (transcutaneous immunization, TCI) mediates systemic peptide-specific cytotoxic T-cell (CTL) responses and leads to tumor protection in a prophylactic tumor setting. However, it does not accomplish memory formation or permanent defiance of tumors in a therapeutic set-up. As a distinct immunologic approach, CTLA-4 blockade augments systemic immune responses and has shown long-lasting effects in preclinical experiments as well as in clinical trials., Objective: The study investigates the vaccination capacity of TCI in combination with the checkpoint inhibitor CTLA-4 in matters of primary response, memory formation and tumor protection and characterizes the role of regulatory T cells (Tregs)., Methods: After performing TCI with IMI-Sol (containing 5% Imiquimod) and the model epitope SIINFEKL, 6-8 week old C57BL/6 mice received anti-CTLA-4 antibody either s.c or i.p. The CTL responses and frequency of peptide specific CD8
+ T-cells were then evaluated on day 8. To determine anti-tumor effects, a therapeutic tumor challenge with B16 OVA melanoma was performed., Results: The combination of s.c. anti-CTLA-4 antibody and TCI leads to an enhanced systemic cytotoxic response, to memory formation and allows significantly improved survival in a tumor setting with B16 OVA melanoma. Towards the mechanism, we show that in this vaccination protocol the CTLA-4 antibody acts mainly Treg-independent., Conclusion: We demonstrate that the combination of TCI with IMI-Sol and anti-CTLA-4 can confer potent immune responses and tumor-protection. These results might contribute to the development of advanced vaccination approaches targeting tumors or persistent infectious diseases., (Copyright © 2017 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
31. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
- Author
-
Lopez PA, Denny M, Hartmann AK, Alflen A, Probst HC, von Stebut E, Tenzer S, Schild H, Stassen M, Langguth P, and Radsak MP
- Subjects
- Administration, Cutaneous, Animals, Cell Movement, Disease Models, Animal, Emulsions, Epitopes immunology, Flow Cytometry, Humans, Imiquimod, Langerhans Cells immunology, Lymphocytic Choriomeningitis immunology, Lymphocytic Choriomeningitis virology, Lymphocytic choriomeningitis virus immunology, Major Histocompatibility Complex immunology, Membrane Glycoproteins genetics, Membrane Glycoproteins metabolism, Mice, Mice, Inbred C57BL, Mice, Knockout, Myeloid Differentiation Factor 88 genetics, Myeloid Differentiation Factor 88 metabolism, Signal Transduction immunology, Skin cytology, Skin drug effects, Skin immunology, Skin Neoplasms immunology, T-Lymphocytes, Cytotoxic immunology, Toll-Like Receptor 7 genetics, Toll-Like Receptor 7 metabolism, Vaccination methods, Aminoquinolines therapeutic use, Langerhans Cells drug effects, Lymphocytic Choriomeningitis prevention & control, Skin Neoplasms prevention & control, T-Lymphocytes, Cytotoxic drug effects
- Abstract
Background: Transcutaneous immunization (TCI) is a novel vaccination strategy utilizing the skin associated lymphatic tissue to induce immune responses. TCI using a cytotoxic T lymphocyte (CTL) epitope and the Toll-like receptor 7 (TLR7) agonist imiquimod mounts strong CTL responses by activation and maturation of skin-derived dendritic cells (DCs) and their migration to lymph nodes. However, TCI based on the commercial formulation Aldara only induces transient CTL responses that needs further improvement for the induction of durable therapeutic immune responses., Objective: Therefore we aimed to develop a novel imiquimod solid nanoemulsion (IMI-Sol) for TCI with superior vaccination properties suited to induce high quality T cell responses for enhanced protection against infections., Methods: TCI was performed by applying a MHC class I or II restricted epitope along with IMI-Sol or Aldara (each containing 5% Imiquimod) on the shaved dorsum of C57BL/6, IL-1R, Myd88, Tlr7 or Ccr7 deficient mice. T cell responses as well as DC migration upon TCI were subsequently analyzed by flow cytometry. To determine in vivo efficacy of TCI induced immune responses, CTL responses and frequency of peptide specific T cells were evaluated on day 8 or 35 post vaccination and protection in a lymphocytic choriomeningitis virus (LCMV) infection model was assessed., Results: TCI with the imiquimod formulation IMI-Sol displayed equal skin penetration of imiquimod compared to Aldara, but elicited superior CD8
+ as well as CD4+ T cell responses. The induction of T-cell responses induced by IMI-Sol TCI was dependent on the TLR7/MyD88 pathway and independent of IL-1R. IMI-Sol TCI activated skin-derived DCs in skin-draining lymph nodes more efficiently compared to Aldara leading to enhanced protection in a LCMV infection model., Conclusion: Our data demonstrate that IMI-Sol TCI can overcome current limitations of previous imiquimod based TCI approaches opening new perspectives for transcutaneous vaccination strategies and allowing the use of this enhanced cutaneous drug-delivery system to be tailored for the improved prevention and treatment of infectious diseases and cancers., (Copyright © 2017 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
32. 9-Phenanthrol enhances the generation of an CD8 + T cell response following transcutaneous immunization with imiquimod in mice.
- Author
-
Hartmann AK, Aranda Lopez P, Zajac M, Freichel M, Schild H, Radsak MP, and Stassen M
- Subjects
- Adjuvants, Immunologic therapeutic use, Administration, Cutaneous, Aminoquinolines pharmacology, Aminoquinolines therapeutic use, Animals, Calcium metabolism, Cell Movement, Dendritic Cells drug effects, Dendritic Cells immunology, Humans, Imiquimod, Immunity, Innate drug effects, Mast Cells immunology, Mast Cells metabolism, Mice, Mice, Inbred C57BL, Mice, Transgenic, Phenanthrenes pharmacology, Phenanthrenes therapeutic use, Protein Kinase Inhibitors therapeutic use, Skin cytology, Skin drug effects, Skin immunology, T-Lymphocytes, Cytotoxic immunology, Vaccination methods, Xenograft Model Antitumor Assays, Adjuvants, Immunologic pharmacokinetics, Cell Degranulation drug effects, Mast Cells drug effects, Melanoma prevention & control, Protein Kinase Inhibitors pharmacology, Skin Neoplasms prevention & control, T-Lymphocytes, Cytotoxic drug effects, TRPM Cation Channels metabolism
- Abstract
Background: Transcutaneous immunization (TCI) is a non-invasive vaccination strategy targeting the skin-associated lymphoid tissue. Topical application of the TLR7 agonist imiquimod as adjuvant in combination with peptide antigens activates the innate immune system and mounts cytotoxic T lymphocyte (CTL) responses., Objective: Based on the commercial 5% imiquimod-containing drug Aldara we aimed to develop an improved formulation with superior vaccination efficiencies. The primary target was the enhancement of mast cell activation as important key for the function of the innate immune system., Methods: We investigated the effects of 9-phenanthrol (9-phe) on the activation of mast cells in vitro and in vivo. For TCI, we applied 0.2% 9-phe in Aldara or Aldara alone as adjuvants in combination with the MHC class I - restricted peptide SIINFEKL. To monitor vaccination, mast cell degranulation, migration of DC and frequencies of epitope-specific CTL was assessed. In a transgenic tumor model, the efficiencies of prophylactic immunization against a tumor antigen were also monitored., Results: 9-phe induced degranulation of mast cells in vitro and upon topical application in vivo. A mixture of 0.2% 9-phe in Aldara showed superior results regarding the migration of DC and the expansion of antigen-specific CTL. Consequently, prophylactic immunization with 0.2% 9-phe in Aldara caused enhanced protection against tumor inoculation., Conclusion: Our data demonstrate that a simple modification of an adjuvant formulation can yield superior results in experimental vaccination protocols by boosting critical steps leading to the generation of an efficient CTL response., (Copyright © 2017 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
33. ADAMTS-13 regulates neutrophil recruitment in a mouse model of invasive pulmonary aspergillosis.
- Author
-
Alflen A, Prüfer S, Ebner K, Reuter S, Aranda Lopez P, Scharrer I, Banno F, Stassen M, Schild H, Jurk K, Bosmann M, Beckert H, and Radsak MP
- Abstract
Von Willebrand factor (VWF) is secreted as an acute phase protein during inflammation. ADAMTS-13 regulates the size and prothrombotic activity of VWF by it's specific proteolytic activity. To determine the relevance of this regulatory pathway for the innate inflammatory response by polymorphonuclear neutrophils (PMN), we employed a mouse model of invasive pulmonary aspergillosis (IPA) where PMN functionality is crucial for fungal clearance and survival. IPA was induced by intratracheal application of Aspergillus fumigatus (A. fumigatus) conidia in wildtype (129/Sv/Pas) or ADAMTS-13 deficient (Adamts13
-/- ) mice. While neutropenic mice developed lethal IPA, all wildtype mice survived the infection. In contrast to wildtype or VWF deficient mice, Adamts13-/- mice displayed more severe signs of disease with a lethal course in 24% with an increased fungal burden and signs of acute lung injury. Histology sections demonstrated a more pronounced perivascular leukocyte infiltration in support of a dysregulated inflammatory response in Adamts13-/- mice. Importantly, we observed no general defect in the activation of neutrophil functions in response to conidia or hyphae in vitro. Therefore, we conclude that the proteolytic regulation of VWF by ADAMTS-13 or ADAMTS-13 by itself is an important mechanism to control PMN recruitment in acute inflammatory processes, such as fungal pneumonias.- Published
- 2017
- Full Text
- View/download PDF
34. The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation.
- Author
-
Stadler N, Hasibeder A, Lopez PA, Teschner D, Desuki A, Kriege O, Weber ANR, Schulz C, Michel C, Heβ G, and Radsak MP
- Subjects
- Adenine analogs & derivatives, Animals, Biomarkers, Humans, Mice, Neutrophil Activation immunology, Neutrophils immunology, Piperidines, Respiratory Burst drug effects, Respiratory Burst genetics, Respiratory Burst immunology, Triggering Receptor Expressed on Myeloid Cells-1 metabolism, Neutrophil Activation drug effects, Neutrophil Activation genetics, Neutrophils drug effects, Neutrophils metabolism, Protein Kinase Inhibitors pharmacology, Pyrazoles pharmacology, Pyrimidines pharmacology, Triggering Receptor Expressed on Myeloid Cells-1 genetics
- Published
- 2017
- Full Text
- View/download PDF
35. Leukocyte-platelet aggregates-a phenotypic characterization of different stages of peripheral arterial disease.
- Author
-
Dopheide JF, Rubrech J, Trumpp A, Geissler P, Zeller GC, Bock K, Dünschede F, Trinh TT, Dorweiler B, Münzel T, Radsak MP, and Espinola-Klein C
- Subjects
- Aged, Aged, 80 and over, Biomarkers, Blood Cell Count, Cell Adhesion Molecules metabolism, Comorbidity, Female, Flow Cytometry, Humans, Lipopolysaccharide Receptors metabolism, Male, Middle Aged, Monocytes metabolism, Neutrophils metabolism, Peripheral Arterial Disease therapy, Receptors, IgG metabolism, Receptors, Immunologic metabolism, Risk Factors, Blood Platelets metabolism, Cell Aggregation, Leukocytes metabolism, Peripheral Arterial Disease blood, Peripheral Arterial Disease diagnosis, Phenotype
- Abstract
The formation of monocyte-platelet aggregates and neutrophil-platelet aggregates (MPA and NPA, respectively) is influenced by inflammation, but also might contribute to an exacerbation of inflammatory responses in atherosclerotic plaque. The purpose of this study was to analyze MPA and NPA proportions in regard to different stages of peripheral arterial disease (PAD). Forty-five patients with intermittent claudication (IC) (3 groups: Rutherford (R)-1, R-2, and R-3; each n = 15), 20 patients with critical limb ischemia (CLI) (Rutherford 5 (40%) and 6 (60%)), and 20 healthy controls were studied. Analyses of monocyte (Mon) subpopulations (CD14++CD16- (classical) Mon1, CD14++CD16+ (intermediate) Mon2, CD14+CD16++ (non-classical) Mon3), MPA, and NPA was performed from whole blood by flow cytometry. Controls showed an increased proportion of the Mon1 subpopulation (p < 0.001), whereas CLI patients showed a significant increase of the Mon2 subpopulation compared to controls, R-1, or R-2 patients (p < 0.0001). For the Mon3 subpopulation, CLI and R-3 patients showed an increased proportion (p < 0.05). MPA formation with the proinflammatory Mon2 and Mon3 subpopulations was increased in CLI patients (both p < 0.01). Similarly, NPA was significantly increased in CLI patients (p < 0.05). Serological markers of inflammation and procoagulation (fibrinogen [r = 0.459, p < 0.001], soluble triggering receptor expressed on myeloid cells (sTREM-1) [r = 0.237, p < 0.05] and P-Selectin [r = 0.225, p < 0.05]) correlated directly with MPA formation on the Mon2 subpopulation. We found an association of inflammatory and procoagulatory markers with increased formation of MPA on the Mon2 subpopulation. Since R-3 patients also had significantly increased MPA, one can speculate that the inflammatory burden might promote an aggravation of the disease.
- Published
- 2016
- Full Text
- View/download PDF
36. Phenotypic and functional characterization of neutrophils and monocytes from patients with myelodysplastic syndrome by flow cytometry.
- Author
-
Schmidt CS, Aranda Lopez P, Dopheide JF, Schmidt F, Theobald M, Schild H, Lauinger-Lörsch E, Nolte F, and Radsak MP
- Subjects
- Aged, Aged, 80 and over, CD11b Antigen metabolism, Cell Degranulation, Cell Separation, Female, Flow Cytometry, Humans, Immunophenotyping, Male, Middle Aged, Monitoring, Immunologic, Monitoring, Physiologic, Myelodysplastic Syndromes immunology, Prognosis, Receptors, IgG metabolism, Monocytes immunology, Myelodysplastic Syndromes diagnosis, Neutrophils immunology
- Abstract
Myelodysplastic syndrome (MDS) is a clonal stem cell disorder frequently associated with inefficient granulopoiesis showing dysplastic polymorphonuclear neutrophils (PMNs). To assess PMN functionality in MDS in a clinical routine setting, 30 MDS patients and ten healthy volunteers were analyzed for PMN and monocyte phenotype and function (degranulation, CD62L shedding, oxidative burst and phagocytosis) upon stimulation with lipopolysaccharide by multi-color flow cytometry (MCFC). Our data show a heterogeneous pattern for CD66, CD16 and CD64 expression on PMNs of MDS patients. CD62L shedding rate and CD66 degranulation were reduced. Interestingly, we detected correlations between the WHO adapted prognostic scoring system (WPSS) and CD16 expression on PMNs as well as the international prognostic scoring system (IPSS) and CD11b degranulation by MCFC, suggesting clinical relevance of MCFC based function testing. In conclusion, MCFC of myelodysplastic immunophenotypes and PMN functionality are applicable in clinical settings, but further prospective studies are needed to assess the practical clinical value of such analyses., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
37. Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents.
- Author
-
Becker M, Graf C, Tonak M, Radsak MP, Bopp T, Bals R, Bohle RM, Theobald M, Rommens PM, Proschek D, and Wehler TC
- Abstract
Undifferentiated pleomorphic sarcoma not otherwise specified belongs to the heterogeneous group of soft tissue tumors. It is preferentially located in the upper and lower extremities of the body, and surgical resection remains the only curative treatment. Preclinical animal models are crucial to improve the development of novel chemotherapeutic agents for the treatment of undifferentiated pleomorphic sarcoma. However, this approach has been hampered by the lack of reproducible animal models. The present study established two xenograft animal models generated from stable non-clonal cell cultures, and investigated the difference in chemotherapeutic effects on tumor growth between undifferentiated pleomorphic sarcoma in vivo and in vitro . The cell cultures were generated from freshly isolated tumor tissues of two patients with undifferentiated pleomorphic sarcoma. For the in vivo analysis, these cells were injected subcutaneously into immunodeficient mice. The mice were monitored for tumor appearance and treated with the most common or innovative chemotherapeutic agents available to date. Furthermore, the same drugs were administered to in vitro cell cultures. The most effective tumor growth inhibition in vitro was observed with doxorubicin and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA), also known as vorinostat. In the in vivo xenograft mouse model, the combination of doxorubicin and the tyrosine kinase inhibitor pazopanib induced a significant tumor reduction. By contrast, treatment with vorinostat did not reduce the tumor growth. Taken together, the results obtained from drug testing in vitro differed significantly from the in vivo results. Therefore, the novel and reproducible xenograft animal model established in the present study demonstrated that in vivo models are required to test potential chemotherapeutic agents for the treatment of undifferentiated pleomorphic sarcoma prior to clinical use, since animal models are more similar to humans, compared with in vitro cell cultures.
- Published
- 2016
- Full Text
- View/download PDF
38. Influence of exercise training on proangiogenic TIE-2 monocytes and circulating angiogenic cells in patients with peripheral arterial disease.
- Author
-
Dopheide JF, Geissler P, Rubrech J, Trumpp A, Zeller GC, Daiber A, Münzel T, Radsak MP, and Espinola-Klein C
- Subjects
- Aged, Female, Humans, Inflammation Mediators blood, Intermittent Claudication blood, Intermittent Claudication diagnosis, Intermittent Claudication physiopathology, Lipids blood, Male, Middle Aged, Peripheral Arterial Disease blood, Peripheral Arterial Disease diagnosis, Peripheral Arterial Disease physiopathology, Pilot Projects, Recovery of Function, Time Factors, Treatment Outcome, Vascular Endothelial Growth Factor A blood, Biomarkers blood, Exercise Therapy, Exercise Tolerance, Intermittent Claudication therapy, Monocytes metabolism, Neovascularization, Physiologic, Peripheral Arterial Disease therapy, Receptor, TIE-2 blood
- Abstract
Background: Inflammation is the driving force in atherosclerosis. One central strategy in the treatment of peripheral arterial disease (PAD) is the promotion of angiogenesis. Here, proangiogenic Tie-2 expressing monocytes (TEM) and circulating angiogenic cells (CAC) play a crucial role. Exercise training (ET) is recommended in PAD patients at Fontaine stage II to promote angiogenesis., Methods: 40 patients with intermittend claudication (IC) [2 groups: supervised ET (SET) vs. non-supervised ET (nSET), each n = 20] and 20 healthy controls were included in the study. Analysis of TEM and CAC was performed from whole blood by flow-cytometry. TEM were identified via CD45, CD86, CD14, CD16 and analysed for the expression of Tie-2. CAC were identified via their expression of CD45 (CD45dim), CD34 and VEGF-R2 (CD309/KDR). Follow up was performed after mean of 7.65 ± 1.62 months., Results: In comparison to healthy controls, we found increased proportions of CAC (p < 0.0001) and similar TEM numbers in both ET groups. At follow-up (FU) TEM poroportions increased (p < 0.001) and CAC proportions decreased (p < 0.01), but both more significantly in SET (p < 0.001) than nSET (p = 0.01). Only in SET fibrinogen levels decreased and VEGF-A increased (both p < 0.05). Finally, we found in both ET groups a significant increase in absolute walking distance but with a higher individual increase in SET (p < 0.01). TEM and CAC proportions correlated inversely with the absolute walking distance (CAC: r = -0.296, p = 0.02; TEM: r = -0.270, p = 0.04) as well as with ABI (CAC: r = -0.394, p < 0.01; TEM: r = -0.382, p < 0.01)., Conclusions: ET influences the distribution of CAC and TEM proportions. nSET, although still effective in regard to an improved walking distance, is less effective in the influence of proangiogenic cells and inflammatory burden than SET. Our results indicate SET to be a more preferential exercise form, supporting the necessity to establish more SET programs.
- Published
- 2016
- Full Text
- View/download PDF
39. The skin as an orchestrator of influenza immunity.
- Author
-
Stein P and Radsak MP
- Subjects
- Female, Humans, Male, Adjuvants, Immunologic administration & dosage, Aminoquinolines administration & dosage, Influenza Vaccines administration & dosage, Influenza, Human immunology, Influenza, Human prevention & control
- Published
- 2016
- Full Text
- View/download PDF
40. Inflammation is associated with a reduced number of pro-angiogenic Tie-2 monocytes and endothelial progenitor cells in patients with critical limb ischemia.
- Author
-
Dopheide JF, Geissler P, Rubrech J, Trumpp A, Zeller GC, Bock K, Dorweiler B, Dünschede F, Münzel T, Radsak MP, and Espinola-Klein C
- Subjects
- Aged, Antigens, CD metabolism, Biomarkers metabolism, Cell Count, Endothelial Progenitor Cells metabolism, Extremities pathology, Female, Flow Cytometry, Follow-Up Studies, Humans, Inflammation complications, Inflammation metabolism, Male, Middle Aged, Neovascularization, Pathologic pathology, Vascular Endothelial Growth Factor Receptor-2 metabolism, Endothelial Progenitor Cells pathology, Extremities blood supply, Inflammation pathology, Ischemia metabolism, Ischemia pathology, Monocytes pathology, Receptor, TIE-2 metabolism
- Abstract
Background: Inflammation is the driving force in atherosclerosis. One central strategy in the treatment for PAD is the promotion of angiogenesis. Here, pro-angiogenic Tie-2-expressing monocytes (TEM) and endothelial progenitor cells (EPC) play a crucial role. Critical limb ischemia (CLI) is characterized by a severe, chronic inflammatory response; thus, progression of the disease might be related to the deleterious effects of inflammation on pro-angiogenic cells., Methods: Forty-five patients with intermittent claudication (IC) [three groups: Rutherford (R)-1, -2, or -3; each n = 15], 20 patients with CLI [n = 20; Rutherford 4 (15 %), 5 (40 %), and 6 (45 %)], and 20 healthy controls were included in the study. Analysis of TEM and EPC was performed from whole blood by flow cytometry. Treatment for IC patients was conservative, and CLI patients underwent surgical revascularization. Follow-up was performed after mean of 7.1 months., Results: In comparison with healthy controls, we found increased proportions of TEM and EPC in dependence of the severity of PAD, with the highest level in patients with severe claudication (R3) (p < 0.01). In contrast, for patients with CLI, we found a significantly reduced expression of both TEM and EPC in comparison with healthy controls (p < 0.05) or IC patients (R-1, R-2, and R-3) (all p < 0.001). At follow-up, TEM and EPC in CLI patients increased significantly (both p < 0.001). Serum levels of fibrinogen and CRP were significantly increased in CLI patients (all p < 0.001), but decreased at follow-up (all p < 0.05). TEM and EPC proportions correlated inversely with levels of fibrinogen [(TEM: r = −0.266; p < 0.01) (EPC: r = −0.297; p < 0.001)], CRP (TEM: r = −0.283; p < 0.01) (EPC: r = −0.260; p < 0.01)., Conclusions: We found a strong association of diverse inflammatory markers with a reduced proportion of pro-angiogenic TEM or EPC in patients with CLI, giving rise to the speculation that a severe chronic inflammation might lead to deleterious effects on TEM and EPC, possibly interfering with angiogenesis, thus promoting an aggravation of the disease.
- Published
- 2016
- Full Text
- View/download PDF
41. Evaluation and Validation of the Detection of soluble Triggering Receptor Expressed on Myeloid Cells 1 by Enzyme-linked immunosorbent Assay.
- Author
-
Hasibeder A, Stein P, Brandwijk R, Schild H, and Radsak MP
- Subjects
- Biomarkers, Complement System Proteins metabolism, Confounding Factors, Epidemiologic, Humans, Protein Isoforms, Reproducibility of Results, Sensitivity and Specificity, Triggering Receptor Expressed on Myeloid Cells-1, Enzyme-Linked Immunosorbent Assay, Membrane Glycoproteins blood, Receptors, Immunologic blood
- Abstract
Triggering receptor expressed on myeloid cells (TREM)-1 plays an important role in innate immune responses and is upregulated under infectious as well as non-infectious conditions. In addition, a soluble TREM-1 variant (sTREM-1) is detectable in sera or bronchoalveolar-lavage fluids from patients. Currently, various studies are difficult to compare, since the methods of detection by enzyme-linked immunosorbent assays (ELISA) vary among different research groups. In this study, we compared three different s-TREM-1 specific ELISAs and identified individual assay characteristics finding notable differences in sTREM-1 concentrations in part depending on the employed buffers. Investigating potential confounding factors for sTREM-1 detection, serum heat-inactivation (HI) showed improved recovery compared to non-HI (NHI) serum, reproducible by addition of complement and re-heat-inactivation. Hence we identified complement as a heat-sensitive confounder in some sTREM-1 ELISAs. We conclude that it is difficult to directly compare data of several studies, in particular if different ELISAs are engaged. Immunoassays for research use only are in general hampered by lack of standardization. Further standardization is needed until sTREM-1 ELISA is capable for better reproducibility of studies and clinical application.
- Published
- 2015
- Full Text
- View/download PDF
42. Change of walking distance in intermittent claudication: impact on inflammation, oxidative stress and mononuclear cells: a pilot study.
- Author
-
Dopheide JF, Scheer M, Doppler C, Obst V, Stein P, Vosseler M, Abegunewardene N, Gori T, Münzel T, Daiber A, Radsak MP, and Espinola-Klein C
- Subjects
- Biomarkers blood, Cell Adhesion Molecules blood, Dendritic Cells immunology, Dendritic Cells metabolism, Exercise Test, Female, Humans, Intermittent Claudication blood, Intermittent Claudication diagnosis, Intermittent Claudication immunology, Intermittent Claudication physiopathology, Leukocytes, Mononuclear immunology, Male, Peripheral Arterial Disease blood, Peripheral Arterial Disease diagnosis, Peripheral Arterial Disease immunology, Peripheral Arterial Disease physiopathology, Phenotype, Pilot Projects, Reactive Oxygen Species blood, Recovery of Function, Time Factors, Treatment Outcome, Exercise Therapy, Exercise Tolerance, Inflammation Mediators blood, Intermittent Claudication therapy, Leukocytes, Mononuclear metabolism, Oxidative Stress, Peripheral Arterial Disease therapy, Walking
- Abstract
Background: Atherosclerosis is a chronic inflammatory process involving the immune system and formation of reactive oxygen species (ROS). We investigated changes of mononuclear blood cells and ROS production in relation to the walking distance of patients with intermittent claudication during home-based exercise training., Methods: Forty patients with intermittent claudication were asked to perform a home-based exercise training for a mean time of 12 months. ROS formation was measured using the luminol analogue L-012. Peripheral blood leucocytes [monocytes, polymorphonuclear neutrophils (PMN) and dendritic cells (DC)] were analysed by flow cytometry and analysed for the expression of major inflammatory surface molecules., Results: At follow-up, patients showed an increased walking distance and reduced ROS production upon stimulation with a phorbol ester derivative (PDBu) (p < 0.01). Monocytes changed their inflammatory phenotype towards an increased anti-inflammatory CD14(++)CD16(-) subpopulation (p < 0.0001). Adhesion molecules CD11b, CD11c and TREM-1 on monocytes and PMN decreased (all p < 0.01). On DC expression of HLA-DR, CD86 or CD40 decreased at follow-up. Inflammatory markers like fibrinogen, C-reactive protein or soluble TREM-1 (sTREM-1) decreased over the observation period. Finally, we found a close relation of sTREM-1 with the walking distance, fibrinogen and ROS production., Conclusions: We observed an amelioration of the proinflammatory phenotype on monocytes, DC and PMN, as well as a reduced ROS production in PAD patients under home-based exercise, paralleled by an increased walking distance. Our data suggest that a reduced inflammatory state might be achieved by regular walking exercise, possibly in a dimension proportionately to changes in walking distance.
- Published
- 2015
- Full Text
- View/download PDF
43. Granulocyte functions are independent of arginine availability.
- Author
-
Kapp K, Prüfer S, Michel CS, Habermeier A, Luckner-Minden C, Giese T, Bomalaski J, Langhans CD, Kropf P, Müller I, Closs EI, Radsak MP, and Munder M
- Subjects
- Animals, Antineoplastic Agents pharmacology, Apoptosis, Arginase blood, Arginase physiology, Arginine analysis, Arginine pharmacology, Aspergillus fumigatus immunology, Bronchoalveolar Lavage Fluid chemistry, Cells, Cultured, Chemotaxis, Leukocyte, Citrulline analysis, Humans, Hydrolases pharmacology, Immunity, Innate, Interleukin-8 biosynthesis, Interleukin-8 genetics, Lung immunology, Lung metabolism, Mice, Mice, Inbred C57BL, Neutrophils cytology, Neutrophils drug effects, Neutrophils enzymology, Phagocytosis, Polyethylene Glycols pharmacology, Primary Cell Culture, Pulmonary Aspergillosis immunology, Pulmonary Aspergillosis metabolism, Reactive Oxygen Species metabolism, Respiratory Burst, Arginine physiology, Neutrophils immunology
- Abstract
Arginine depletion via myeloid cell arginase is critically involved in suppression of the adaptive immune system during cancer or chronic inflammation. On the other hand, arginine depletion is being developed as a novel anti-tumor metabolic strategy to deprive arginine-auxotrophic cancer cells of this amino acid. In human immune cells, arginase is mainly expressed constitutively in PMNs. We therefore purified human primary PMNs from healthy donors and analyzed PMN function as the main innate effector cell and arginase producer in the context of arginine deficiency. We demonstrate that human PMN viability, activation-induced IL-8 synthesis, chemotaxis, phagocytosis, generation of ROS, and fungicidal activity are not impaired by the absence of arginine in vitro. Also, profound pharmacological arginine depletion in vivo via ADI-PEG20 did not inhibit PMN functions in a mouse model of pulmonary invasive aspergillosis; PMN invasion into the lung, activation, and successful PMN-dependent clearance of Aspergillus fumigatus and survival of mice were not impaired. These novel findings add to a better understanding of immunity during inflammation-associated arginine depletion and are also important for the development of therapeutic arginine depletion as anti-metabolic tumor therapy., (© 2014 Society for Leukocyte Biology.)
- Published
- 2014
- Full Text
- View/download PDF
44. Interruption of macrophage-derived IL-27(p28) production by IL-10 during sepsis requires STAT3 but not SOCS3.
- Author
-
Bosmann M, Russkamp NF, Strobl B, Roewe J, Balouzian L, Pache F, Radsak MP, van Rooijen N, Zetoune FS, Sarma JV, Núñez G, Müller M, Murray PJ, and Ward PA
- Subjects
- Adaptor Proteins, Vesicular Transport genetics, Adaptor Proteins, Vesicular Transport metabolism, Animals, Antibodies, Blocking administration & dosage, Bacterial Load, Cecum surgery, Cells, Cultured, Disease Models, Animal, Humans, Interleukin-10 genetics, Interleukins immunology, Macrophages drug effects, Macrophages microbiology, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Myeloid Differentiation Factor 88 genetics, Myeloid Differentiation Factor 88 metabolism, Oxidative Stress drug effects, Oxidative Stress genetics, Receptors, Cytokine genetics, Receptors, Interleukin, STAT3 Transcription Factor genetics, Suppressor of Cytokine Signaling 3 Protein, Suppressor of Cytokine Signaling Proteins genetics, Suppressor of Cytokine Signaling Proteins metabolism, Toll-Like Receptor 4 immunology, Interleukin-10 metabolism, Interleukins metabolism, Macrophages physiology, STAT3 Transcription Factor metabolism, Sepsis immunology
- Abstract
Severe sepsis and septic shock are leading causes of morbidity and mortality worldwide. Infection-associated inflammation promotes the development and progression of adverse outcomes in sepsis. The effects of heterodimeric IL-27 (p28/EBI3) have been implicated in the natural course of sepsis, whereas the molecular mechanisms underlying the regulation of gene expression and release of IL-27 in sepsis are poorly understood. We studied the events regulating the p28 subunit of IL-27 in endotoxic shock and polymicrobial sepsis following cecal ligation and puncture. Neutralizing Abs to IL-27(p28) improved survival rates, restricted cytokine release, and reduced bacterial burden in C57BL/6 mice during sepsis. Genetic disruption of IL-27 signaling enhanced the respiratory burst of macrophages. Experiments using splenectomized mice or treatment with clodronate liposomes suggested that macrophages in the spleen may be a significant source of IL-27(p28) during sepsis. In cultures of TLR4-activated macrophages, the frequency of F4/80(+)CD11b(+)IL-27(p28)(+) cells was reduced by the addition of IL-10. IL-10 antagonized both MyD88-dependent and TRIF-dependent release of IL-27(p28). Genetic deletion of STAT3 in Tie2-Cre/STAT3flox macrophages completely interrupted the inhibition of IL-27(p28) by IL-10 after TLR4 activation. In contrast, IL-10 remained fully active to suppress IL-27(p28) with deletion of SOCS3 in Tie2-Cre/SOCS3flox macrophages. Blockade of IL-10R by Ab or genetic deficiency of IL-10 resulted in 3-5-fold higher concentrations of IL-27(p28) in endotoxic shock and polymicrobial sepsis. Our studies identify IL-10 as a critical suppressing factor for IL-27(p28) production during infection-associated inflammation. These findings may be helpful for a beneficial manipulation of adverse IL-27(p28) release during sepsis., (Copyright © 2014 by The American Association of Immunologists, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
45. Host-derived CD8⁺ dendritic cells protect against acute graft-versus-host disease after experimental allogeneic bone marrow transplantation.
- Author
-
Weber M, Rudolph B, Stein P, Yogev N, Bosmann M, Schild H, and Radsak MP
- Subjects
- Animals, CD8-Positive T-Lymphocytes cytology, Dendritic Cells cytology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Bone Marrow Transplantation methods, CD8-Positive T-Lymphocytes immunology, Dendritic Cells immunology, Dendritic Cells transplantation, Graft vs Host Disease prevention & control, Transplantation, Homologous methods
- Abstract
Graft-versus-host disease (GVHD) is a frequent life-threatening complication after allogeneic hematopoietic stem cell transplantation (HSCT) and induced by donor-derived T cells that become activated by host antigen-presenting cells. To address the relevance of host dendritic cell (DC) populations in this disease, we used mouse strains deficient in CD11c(+) or CD8α(+) DC populations in a model of acute GVHD where bone marrow and T cells from BALB/c donors were transplanted into C57BL/6 hosts. Surprisingly, a strong increase in GVHD-related mortality was observed in the absence of CD11c(+) cells. Likewise, Batf3-deficient (Batf3(-/-)) mice that lack CD8α(+) DCs also displayed a strongly increased GVHD-related mortality. In the absence of CD8α(+) DCs, we detected an increased activation of the remaining DC populations after HSCT, leading to an enhanced priming of allogeneic T cells. Importantly, this was associated with reduced numbers of regulatory T cells and transforming growth factor-β levels, indicating an aggravated failure of peripheral tolerance mechanisms after HSCT in the absence of CD8α(+) DCs. In summary, our results indicate a critical role of CD8α(+) DCs as important inducers of regulatory T cell-mediated tolerance to control DC activation and T cell priming in the initiation phase of GVHD., (Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
46. Efficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulation.
- Author
-
Stein P, Gogoll K, Tenzer S, Schild H, Stevanovic S, Langguth P, and Radsak MP
- Subjects
- Adjuvants, Immunologic pharmacokinetics, Administration, Cutaneous, Aminoquinolines pharmacokinetics, Animals, Cell Line, Tumor, Emulsions, Female, Gels, Imiquimod, Male, Mice, Inbred C57BL, Neoplasm Transplantation, Ovalbumin immunology, Peptide Fragments immunology, Skin Absorption, Thymoma therapy, Adjuvants, Immunologic administration & dosage, Aminoquinolines administration & dosage, Cancer Vaccines administration & dosage, T-Lymphocytes, Cytotoxic immunology, Vaccination
- Abstract
Background: Transcutaneous immunization (TCI) approaches utilize skin associated lymphatic tissues to elicit specific immune responses. In this context, the imidazoquinoline derivative imiquimod formulated in Aldara applied onto intact skin together with a cytotoxic T lymphocyte (CTL) epitope induces potent CTL responses. However, the feasibility and efficacy of the commercial imiquimod formulation Aldara is limited by its physicochemical properties as well as its immunogenicity., Methodology/principal Findings: To overcome these obstacles, we developed an imiquimod-containing emulsion gel (IMI-Gel) and characterized it in comparison to Aldara for rheological properties and in vitro mouse skin permeation in a Franz diffusion cell system. Imiquimod was readily released from Aldara, while IMI-Gel showed markedly decreased drug release. Nevertheless, comparing vaccination potency of Aldara or IMI-Gel-based TCI in C57BL/6 mice against the model cytotoxic T-lymphocyte epitope SIINFEKL, we found that IMI-Gel was equally effective in terms of the frequency of peptide-specific T-cells and in vivo cytolytic activity. Importantly, transcutaneous delivery of IMI-Gel for vaccination was clearly superior to the subcutaneous or oral route of administration. Finally, IMI-Gel based TCI was at least equally effective compared to Aldara-based TCI in rejection of established SIINFEKL-expressing E.G7 tumors in a therapeutic setup indicated by enhanced tumor rejection and survival., Conclusion/significance: In summary, we developed a novel imiquimod formulation with feasible pharmaceutical properties and immunological efficacy that fosters the rational design of a next generation transcutaneous vaccination platform suitable for the treatment of cancer or persistent virus infections.
- Published
- 2014
- Full Text
- View/download PDF
47. Donor and host B cell-derived IL-10 contributes to suppression of graft-versus-host disease.
- Author
-
Weber M, Stein P, Prüfer S, Rudolph B, Kreft A, Schmitt E, Bopp T, Roers A, Schild H, Fillatreau S, and Radsak MP
- Subjects
- Allografts, Animals, B-Lymphocytes pathology, Dendritic Cells pathology, Graft vs Host Disease genetics, Graft vs Host Disease pathology, Interleukin-10 genetics, Mice, Mice, Inbred BALB C, Mice, Knockout, T-Lymphocytes pathology, B-Lymphocytes immunology, Dendritic Cells immunology, Graft vs Host Disease immunology, Hematopoietic Stem Cell Transplantation, Interleukin-10 immunology, T-Lymphocytes immunology
- Abstract
Graft-versus-host disease (GvHD) is a frequent life-threatening complication following allogeneic HSC transplantation (HSCT). IL-10 is a regulatory cytokine with important roles during GvHD, yet its relevant sources, and mode of action, remain incompletely defined in this disease. Using IL-10-deficient donor or host mice (BALB/c or C57BL/6, respectively) in a MHC-mismatched model for acute GvHD, we found a strongly aggravated course of the disease with increased mortality when either donor or host cells could not produce this cytokine. A lack of IL-10 resulted in increased allogeneic T-cell responses and enhanced activation of host DCs in spleen and MLNs. Remarkably, IL-10 was prominently produced by host- and donor-derived CD5(int) CD1d(int) TIM-1(int) B cells in this disease, and consistent with this, allogeneic HSCT resulted in exacerbated GvHD when mice lacking IL-10 expression in B cells were used as donor or host, compared with controls. Taken together, this study demonstrates that host and donor B cell-derived IL-10 provides a unique mechanism of suppression of acute GvHD, and suggests that DCs are the targets of this B cell-mediated suppressive effect. These findings open novel therapeutic possibilities based on the use of B cells to increase the feasibility of allogeneic HSCT., (© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2014
- Full Text
- View/download PDF
48. Oxidative burst and neutrophil elastase contribute to clearance of Aspergillus fumigatus pneumonia in mice.
- Author
-
Prüfer S, Weber M, Stein P, Bosmann M, Stassen M, Kreft A, Schild H, and Radsak MP
- Subjects
- Animals, Antigens, Fungal immunology, Cell Movement genetics, Cells, Cultured, Humans, Immunity, Cellular genetics, Leukocyte Elastase genetics, Lung microbiology, Membrane Glycoproteins genetics, Membrane Glycoproteins metabolism, Mice, Mice, 129 Strain, Mice, Inbred C57BL, Mice, Knockout, NADPH Oxidase 2, NADPH Oxidases genetics, NADPH Oxidases metabolism, Neutrophils microbiology, Oxidative Stress genetics, Aspergillus fumigatus physiology, Invasive Pulmonary Aspergillosis immunology, Leukocyte Elastase metabolism, Lung pathology, Neutrophils immunology
- Abstract
Polymorphonuclear neutrophils (PMN) are important for the control of invasive aspergillosis (IA), a major threat to immunocompromised individuals. For clearance of Aspergillus fumigatus infections, PMN employ their potent oxidative and non-oxidative mechanisms. To clarify the relative contribution of these mechanisms, we analyzed p47(phox-/-), gp91(phox-/-) and elastase (ELA) deficient mice (ELANE) after intratracheal infection with A. fumigatus. Infected p47(phox-/-) and gp91(phox-/-) mice died within 4 days and had a significant higher fungal burden in the lungs compared to wild-type controls. Interestingly, the survival of ELANE mice after infection was unimpaired suggesting that ELA is not essential here. Nevertheless, A. fumigatus clearance was delayed in ELANE mice indicating a partial contribution of ELA to fungal immunity. Comparing p47(phox-/-), gp91(phox-/-) or ELANE mice for PMN activation and recruitment to the lungs, we were unable to detect significant differences in vitro or in vivo among mutant or wild-type strains suggesting intact PMN functionality of basic effector mechanisms. Fungal killing in vitro by ELA deficient PMN was comparably reduced as in p47(phox-/-) and gp91(phox-/-) deficient PMN corroborating the importance of oxidative and non-oxidative PMN mechanisms for the control of fungal outgrowth. Taken together, this suggests that intact oxidative as well as non-oxidative PMN effector functions are highly relevant for the control of A. fumigatus infections in vitro and in vivo. While ELA contributes to clearance of A. fumigatus, the oxidative functions are essential for survival., (Copyright © 2013 Elsevier GmbH. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
49. Distinct signaling cascades of TREM-1, TLR and NLR in neutrophils and monocytic cells.
- Author
-
Prüfer S, Weber M, Sasca D, Teschner D, Wölfel C, Stein P, Stassen M, Schild H, and Radsak MP
- Subjects
- Cell Line, Tumor, Cytokines metabolism, Extracellular Signal-Regulated MAP Kinases metabolism, Humans, Immunity, Innate, Inflammation Mediators metabolism, Organ Specificity, Phosphatidylinositol 3-Kinases metabolism, Toll-Like Receptors metabolism, Triggering Receptor Expressed on Myeloid Cells-1, p38 Mitogen-Activated Protein Kinases metabolism, Calcium Signaling, Leukemia, Myeloid, Acute immunology, Membrane Glycoproteins metabolism, Monocytes immunology, Neutrophils immunology, Receptors, Immunologic metabolism
- Abstract
Triggering receptor expressed on myeloid cells 1 (TREM-1) is an important mediator of innate inflammatory responses in microbial infections and sepsis. TREM-1 ligation on neutrophils (PMN) or monocytes results in the production of proinflammatory cytokines. Engagement of TREM-1 induces the activation of MAP kinases as well as rapid Ca(2+) mobilization. However, a detailed understanding of TREM-1 signaling pathways is currently lacking. We evaluated the TREM-1 signaling hierarchy in monocytic cells and found that the acute myeloid leukemia cell line MUTZ-3 expresses TREM-1 in a natural and functional manner. We compared essential signaling molecules of the TREM-1, TLR and NLR cascade in MUTZ-3 cells as well as primary monocytes or PMN by Western blot analysis. These studies confirmed the essential role of phosphatidyl inositide 3-kinase (PI3K) and p38MAPK in the TREM-1 as well as the TLR or NLR cascade of monocytic cells. Importantly, PI3K and p38MAPK signals in monocytic cells both control Ca(2+) mobilization and are directly connected in the TREM-1 signaling hierarchy, which contrasts previous results obtained in PMN. Taken together, our results indicate cell type-specific differences in the TREM-1 signaling cascade and contribute to an enhanced understanding of the regulation of innate inflammatory responses., (© 2013 S. Karger AG, Basel.)
- Published
- 2014
- Full Text
- View/download PDF
50. Mast cell-derived mediators promote murine neutrophil effector functions.
- Author
-
Doener F, Michel A, Reuter S, Friedrich P, Böhm L, Relle M, Codarri L, Tenzer S, Klein M, Bopp T, Schmitt E, Schild H, Radsak MP, Taube C, Stassen M, and Becker M
- Subjects
- Animals, Apoptosis, Cells, Cultured, Flow Cytometry, Granulocyte-Macrophage Colony-Stimulating Factor genetics, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Mutant Strains, Neutrophil Activation genetics, Phagocytosis genetics, Tumor Necrosis Factor-alpha genetics, Granulocyte-Macrophage Colony-Stimulating Factor metabolism, Mast Cells immunology, Neutrophils immunology, Pneumonia immunology, Tumor Necrosis Factor-alpha metabolism
- Abstract
Mast cells are able to trigger life-saving immune responses in murine models for acute inflammation. In such settings, several lines of evidence indicate that the rapid and protective recruitment of neutrophils initiated by the release of mast cell-derived pro-inflammatory mediators is a key element of innate immunity. Herein, we investigate the impact of mast cells on critical parameters of neutrophil effector function. In the presence of activated murine bone marrow-derived mast cells, neutrophils freshly isolated from bone marrow rapidly lose expression of CD62L and up-regulate CD11b, the latter being partly driven by mast cell-derived TNF and GM-CSF. Mast cells also strongly enhance neutrophil phagocytosis and generation of reactive oxygen species. All these phenomena partly depend on mast cell-derived TNF and to a greater extend on GM-CSF. Furthermore, spontaneous apoptosis of neutrophils is greatly diminished due to the ability of mast cells to deliver antiapoptotic GM-CSF. Finally, we show in a murine model for acute lung inflammation that neutrophil phagocytosis is impaired in mast cell-deficient Kit (W-sh) /Kit (W-sh) mice but can be restored upon mast cell engraftment. Thus, a previously underrated feature of mast cells is their ability to boost neutrophil effector functions in immune responses.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.